WHO SMART Guidelines - HIV
0.4.3 - ci-build
WHO SMART Guidelines - HIV - Local Development build (v0.4.3) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
This page includes indicators and performance metrics aggregated from core data elements identified and is extracted from the WHO Digital Adaptation Kit (DAK) SMART Guidelines for HIV .
For full operational descriptions of the indicators included and their references, see Web Annex C of the HIV DAK.
For machine-readable representations, see the Indicators and Measures.
These indicators may be aggregated automatically from the digital tracking tool to populate a digital health management information system (HMIS).
| Data Element | Description |
|---|---|
| DAK ID | Sequential numbering of the indicator, as used in the HIV DAK. This unique identifier facilitates tracking and referencing each indicator within the kit. |
| Ref no. | Identifier of the indicator in the 2022 HIV Strategic Information Guidelines. This number is used for cross-referencing with official guidance. |
| Short name | A brief, clear name for the indicator that succinctly captures its focus. |
| Indicator definition | A concise description outlining the purpose and scope of the indicator. It explains what the indicator is intended to measure. |
| Category | The classification or grouping of the indicator as defined in the HIV DAK. This helps organize indicators by thematic areas or focus. |
| What it measures | A detailed narrative that provides additional context on the specific aspect or phenomenon the indicator tracks. |
| Rationale | The strategic reasoning behind the indicator, including its importance for monitoring and evaluating HIV-related outcomes. |
| Numerator definition | A detailed explanation of the numerator, including how it is derived and any specific data elements involved. This description is based on the guidelines. |
| Numerator calculation | A clear, step-by-step description of how the numerator is computed. This should include any logic, conditions, or filtering criteria applied to the data. |
| Denominator definition | A detailed explanation of what constitutes the denominator, referring to the guideline definition to clarify the scope of the measure. |
| Denominator calculation | A clear explanation of how the denominator is computed, outlining the logical steps and data elements used in its derivation. |
| Disaggregation description | A comprehensive description of how the indicator can be broken down (e.g., by age, sex, administrative area) in line with the 2022 Consolidated Guidelines on person-centered HIV strategic information. |
| Reference | The source or citation for the indicator, including any guidelines, documents, or publications that provide additional context or justification. |
The following indicators are extracted from the HIV DAK. The full indicators and performance metrics table is available in Web Annex C of the HIV DAK. To see linkages to references and full details of the L2 content, please reference the HIV DAK.
| DAK ID | Ref no. | Short name | Indicator definition | Category | What it measures | Rationale | Numerator definition | Numerator calculation | Denominator definition | Denominator calculation | Disaggregation description | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV.IND.1 | PRV.1 | Condoms distributed | Total number of condoms distributed during the reporting period | HIV prevention | This indicator measures the number of condoms distributed through different modalities. | • Proactive distribution of condoms is a strategy for ensuring adequate availability. • By analysing the proportion of condoms distributed through different modalities, national programmes can optimize their investment in socially marketed and public-sector (that is, free) condom distribution. | Total number of condoms distributed and sold during the reporting period | Not included in DAK; from multiple data sources | 1 | Not included in DAK | • Condom type (male, female) • Distribution type (commercial sector, social marketing, public sector) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.2 | PRV.2 | Total PrEP recipients | Number of people who received PrEP at least once during the reporting period | HIV prevention | This indicator measures the number of people receiving any PrEP product during the reporting period, including people starting PrEP for the first time, restarting PrEP, continuing PrEP or switching from one PrEP product to another. | • The use of ARV medicines by people who are HIV-negative before they are exposed to HIV can prevent HIV infection. • Through disaggregation, this indicator can help managers compare the uptake and use of PrEP among different types of users (for example, by first-time users, and members of priority populations). | Number of people prescribed or dispensed any form of PrEP at least once during the reporting period. Individuals prescribed different PrEP products or regimens at different times during the reporting period should be counted only once. | COUNT of clients with "Medications prescribed"='PrEP for HIV prevention' with "Date medications prescribed" in the reporting period | 1 | 1 | • Age (15–19, 20–24, 25–49, 50+ years) • Gender (female, male, other*) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • PrEP product and formulation (oral, long-acting device, long-acting injectable). Some people may start, continue, stop and restart, one or multiple times with different products or formulations in a given reporting period. Because of this, the percentages of recipients receiving different PrEP products may total more than 100%. • Experience with PrEP (first time, continuing, or restarting following a period of not taking PrEP) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.3 | PRV.3 | PrEP coverage | % of people prescribed PrEP among those identified as being at elevated risk for HIV acquisition | HIV prevention | Measures PrEP uptake among the group estimated to be vulnerable to HIV acquisition. When calculated at the programme/service provider level, the denominator includes all individuals accessing the service identified as being at elevated risk for to HIV acquisition. | • WHO recommends that PrEP be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches. • Uptake and use of PrEP reflects people's awareness and interest in lowering their risk for HIV through the use of ARVs. | Number of unique individuals prescribed or dispensed any form of PrEP at least once during the reporting period. Individuals prescribed different products or regimens at different times during the reporting period should be counted only once. | Count of clients with "Date medications prescribed" within reporting period AND "Medications prescribed"='PrEP for HIV prevention' | a) Programme/service provider level: number of individuals who received a negative HIV test during the reporting period and identified as being at elevated risk for HIV acquisition (includes people requesting/receiving any HIV prevention intervention, people from key populations, people with known risk factors or assessed as being at risk of HIV acquisition) b) Population level: population-level estimate of the number of people who would benefit from PrEP, for example as derived from a PrEP need estimator tool | Programme/service provider level: COUNT of clients with "HIV test date" within reporting period AND "HIV test result"='HIV-negative' AND "At elevated risk for HIV acquisition"=True † Population level: \*Estimate of the number of people who would benefit from PrEP | • Gender (female, male, other*) • Age (15–19, 20–24, 25–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • PrEP product and formulation (oral, long-acting device, long-acting injectable). Some people may start, continue, stop and restart, one or multiple times with different products or formulations in a given reporting period. Because of this, the percentages of recipients receiving different PrEP products may total more than 100%. • Experience with PrEP (first time, continuing or restarting following a period of not taking PrEP) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.4 | PRV.4 | Volume of PrEP prescribed | Total volume of PrEP product prescribed | HIV prevention | The total volume of PrEP product prescribed can be used to forecast future commodity needs. | The total volume of PrEP product prescribed or dispensed can be used to calculate the total number of days (or months/years) available for product use, which can be used derive indicators examining the level of PrEP provided relative to need. | The total sum of the volume of PrEP product prescribed for each PrEP recipient during the reporting period | SUM of "Number of days prescribed" for all clients with "Medications prescribed"='PrEP for HIV prevention' | 1 | 1 | • Gender (female, male, other*) • Age (15–19, 20–24, 25–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • PrEP product and formulation (oral, long-acting device, long-acting injectable) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.5 | PRV.5 | Number of PEP recipients | Number of people prescribed PEP during the reporting period | HIV prevention | Measure of total number of individuals receiving PEP in a defined period. | PEP should be offered and initiated as early as possible for all individuals with an exposure that has the potential for HIV transmission, preferably within 72 hours. | Number of people prescribed PEP during the reporting period | COUNT of clients with "Medications prescribed"='PEP for HIV prevention' AND "Date medications prescribed" within the reporting period | 1 | 1 | • Gender (female, male, other*) • Age (15-19, 20-24, 25-49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)2 • Exposure type (occupational, non-occupational violent, non-occupational consensual sex) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.6 | PRV.6 | PEP completion | % of PEP recipients completing PEP course | HIV prevention | This indicator measures the successful completion of PEP among all PEP recipients in a defined period. | Individuals should be provided with adherence support to increase rates of completion of HIV PEP. | Number of people completing a course of PEP among those starting in reporting period | COUNT of clients with "Medications prescribed"='PEP for HIV prevention' AND "Date client completes PEP course" within the reporting period | Number of people starting PEP during the reporting period, excluding those whose PEP course is due to be completed after the end of the reporting period | COUNT of clients with "Medications prescribed"='PEP for HIV prevention' AND "Date medications prescribed" within reporting period (or with expected completion date in the reporting period) | • Gender (female, male, other*) • Age (15-19, 20-24, 25-49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)2 • Exposure type (occupational, non-occupational violent, non-occupational consensual sex) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.7 | PRV.7 | HIV in PEP recipients | % of PEP recipients testing HIV-positive three months after PEP was prescribed | HIV prevention | This indicator measures HIV infection status among individuals after receiving PEP. | WHO recommends all individuals potentially exposed to HIV should be encouraged to undergo HIV testing three months following the exposure. | Number of people testing positive for HIV three months after receiving PEP during the reporting period | COUNT of clients with "Medications prescribed"='PEP for HIV prevention' AND "Date medications prescribed" [for PEP] within reporting period AND "HIV test date" LESS THAN 3 months after "Date medications prescribed" [for PEP] AND "HIV test result"='HIV-positive' | Number of people receiving PEP during the observation period. To allow for observation of a 3-month test result, the observation period must be set at least three months prior. | COUNT of clients with "Medications prescribed"='PEP for HIV prevention' AND "Date medications prescribed" [for PEP] within reporting period | • Gender (female, male, other*) • Age (15-19, 20-24, 25-49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender -diverse people)2 • Exposure type (occupational, non-occupational violent, non-occupational consensual sex) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.8 | PRV.8 | NSP coverage | % of people who inject drugs provided with needles-syringes during the reporting period | HIV prevention | This indicator measures access to needle–syringe programmes by people who inject drugs, measured either at the programme or service provider level among individuals accessing HIV prevention services, or at the population level using relevant estimates of the population size of people who inject drugs. | People who inject drugs require ongoing access to needles–syringes. Needle-syringe programmes should be accessible and achieve good coverage among people who inject drugs. | Number of people receiving needles-syringes during the reporting period | COUNT of clients with "Key population member type"='People who inject drugs' AND with "Date injecting equipment provided" within the reporting period | a) Programme/service provider level: number of people who inject drugs who access the service b) Population level: population size estimate of people who inject drugs in relevant geographic area | Programme/service level: COUNT of clients with "Key population member type"='People who inject drugs' Population level: \*Estimated number of people who inject drugs | • Gender (female, male, other*) • Age (<25, 25+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.9 | PRV.9 | Regular NSP access | % of people who inject drugs accessing a needle-syringe programme (NSP) at least once per month during the reporting period | HIV prevention | This indicator measures the frequency that people who inject drugs access a NSP. | Frequent and regular access to an NSP by people who inject drugs is encouraged to ensure availability of sterile injecting equipment. | Total number of people receiving needles-syringes at least once per month during the reporting period, either: a) number of people accessing an NSP at least once in each 30-day period of the reporting period b) number of people accessing an NSP at least once per month on average during the reporting period | COUNT of clients with "Date injecting equipment provided" within each 30 day period of reporting period | a) Programme/service provider level: number of people who inject drugs accessing service b) Population level: population-size estimate of people who inject drugs in relevant geographic area | Programme/service level: COUNT of clients with "Key population member type"='People who inject drugs' Population level: \*Estimated number of people who inject drugs | • Gender (female, male, other*) • Age (<25, 25+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.10 | PRV.10 | Needles–syringes distributed | Number of needles–syringes distributed per year per person who injects drugs | HIV prevention | Measure of the quantity of needles–syringes distributed through needle–syringe programmes. When measured at the programme/service provider level among people who inject drugs accessing needle–syringe programmes, this indicator measures the average volume of needles–syringes provided per person who inject drugs. Measured at the population level, this indicator measures the total number of clean units of injecting equipment in circulation that might be used by the overall population of people who inject drugs, noting that secondary distribution of equipment within networks is a significant source of sterile equipment among people who inject drugs. | • When measured at the population level with a denominator that is the estimated number of people who inject drugs, this indicator allows understanding of the country's progress towards national coverage of needle–syringe programmes for all people who inject drugs. • When measured at the programme/service provider level with the denominator that is the number of people who inject drugs reached by the programme, this indicator allows understanding of the quality of the programme and whether adequate needle–syringes are being distributed to programme recipients. | a) number of needles-syringes distributed by NSPs in the reporting period b) number of needles-syringes sold to people who inject drugs by pharmacies or other outlets in the reporting period | Not included in DAK; from multiple data sources | a) Programme/service provider level: number of people who inject drugs accessing service b) Population level: population-size estimate of people who inject drugs in relevant geographic area | • Gender (female, male, other*) • Age (<25, 25+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.11 | PRV.11 | OAMT coverage | % of opioid dependent people receiving opioid agonist maintenance treatment (OAMT) at a specified date | HIV prevention | Measure of the coverage of OAMT among people who are opioid dependent. Measured at either the service provider or population level. | By providing a direct method of reducing the number of injection risk acts per person who inject drugs, OAMT is a critical component of effective harm reduction services. | Number of people on OAMT at specified census date | Number of clients with "Key population member type"='People who inject drugs' AND "Currently on OAMT"=True for a specific "Reporting date" | a) Programme/service provider level: number of opioid dependent people accessing service b) Population level: population size estimate of opioid dependent people in relevant geographic area | Programme/service provider level: COUNT of opioid dependent people accessing service Population level: \*Estimated population size of opioid dependent people in relevant geographic area | • Gender (female, male, other*) • Age (<25, 25+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.12 | PRV.12 | Total person-years on OAMT | % of person-years of follow-up (PYFU) on OAMT among opioid dependent people | HIV prevention | Measure of the proportion of person time in which individuals who are opioid dependent are covered by OAMT. | Evidence demonstrates that HIV risk is reduced among individuals who are opioid dependent during periods when receiving OAMT. | Total PYFU on OAMT during defined reporting period. Calculated from the sum of the time on OAMT of each OAMT recipient during the reporting period. | SUM of [DIFFERENCE in MIN("Date OAMT initiated", "Reporting period start date") and MAX("Date of loss to follow-up or OAMT stopped", "Reporting period end date")] for all clients with "Medications prescribed" IN 'Methadone', 'Buprenorphine' | a) Programme/service provider level: estimated PYFU for all opioid dependent people accessing service during defined reporting period b) Population level: estimated PYFU for total population of opioid dependent people in relevant geographic area during defined reporting period | Service level: Not calculated in DAK Population denominator: \*Estimated PYFU for all opioid-dependent people accessing service during defined reporting period Note: Can be reported only as numerator; by population or service level if these denominator estimates available. | • Gender (female, male, other*) • Age (15–19, 20–24, 25–49, 50+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.13 | PRV.13 | OAMT minimum duration | % of OAMT recipients who received treatment for at least six months | HIV prevention | This indicator uses a cohort analysis to measure the proportion of OAMT recipients retained on treatment for at least six months and is a measure of how OAMT is prescribed and of retention in the OAMT programme. | Evidence demonstrates that maximum benefit from OAMT is gained when treatment lasts at least six months. | Number of people in cohort retained in OAMT for at least six months | COUNT of clients within cohort "Retained on OAMT"=True 6 months after "Date OAMT initiated" | Number of people starting OAMT during defined cohort recruitment period | COUNT of clients within cohort with "Date OAMT initiated" in cohort recruitment period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–49, 50+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.14 | PRV.14 | OAMT minimum dose | % of OAMT recipients receiving a maintenance dose greater than or equal to the recommended minimum dose | HIV prevention | Measures the proportion of OAMT recipients receiving the recommended minimum maintenance dose. | Evidence demonstrates that maximum benefit from OAMT is gained when individuals receive at least the recommended minimum maintenance dose. | Number of people, at a specified date, maintained on methadone or buprenorphine receiving recommended minimum maintenance dose (WHO guidance recommends doses of ≥60 mg of methadone or ≥8 mg of buprenorphine*) | COUNT of clients with ("Medications prescribed"='Methadone' AND "Dose of medications prescribed" GREATER THAN OR EQUAL TO 60mg) OR ("Medications prescribed"='Buprenorphine' AND "Dose of medications prescribed" GREATER THAN OR EQUAL TO 8mg) for a specified "Reporting date" | Number of people receiving maintenance dose of methadone or buprenorphine at a specified date, excluding: a) individuals currently being inducted on OAMT and yet to reach the maintenance dose and b) individuals on reducing doses of OAMT. | COUNT of clients with "Medications prescribed" IN 'Methadone', 'Buprenorphine' for a specified "Reporting date" | • Gender (female, male, other**) • Age (15–19, 20–24, 25–49, 50+ years) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.15 | PRV.15 | VMMC scale-up | Total number of voluntary medical male circumcisions (VMMCs) performed according to national standard during the reporting period | HIV prevention | This indicator measures progress in scaling up male circumcision services. | WHO and UNAIDS recommend VMMC as an efficacious intervention for HIV prevention in priority* countries and regions with high HIV prevalence and low male circumcision prevalence. Randomized controlled trials have shown that VMMC provided by trained health professionals with proper equipment can reduce the risk of men heterosexually acquiring HIV infection. | Total number of people undergoing VMMC performed according to national standard during the reporting period | COUNT of clients with a "VMMC procedure date" in the reporting period | 1 | 1 | • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years) • HIV status (positive, negative) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.16 | PRV.16 | VMMC adverse events | a) Number or (b) % of adverse events during the reporting period | HIV prevention | • This indicator measures whether VMMC services meet national standards of safety and effectiveness. | • Staff conducting medical circumcisions must have appropriate training and access to proper equipment. • Trends in adverse events may indicate where service providers need additional support. • Intraoperative adverse events may include pain, excessive bleeding, anaesthesia-related effects, excessive skin removal, damage to the penis, sharps injury to personnel. Postoperative adverse events may include abnormal pain, excessive swelling, infection, haematoma, bleeding, difficulty urinating, wound disruption, scar or disfigurement, injury to glans, excessive skin removal. • Moderate or severe adverse events include complications resulting in death or hospitalization within 30 days or permanent disability. | Number of people experiencing at least one moderate or severe adverse event during or following circumcision surgery during the reporting period | COUNT of clients with "VMMC procedure date" in the reporting period AND "Adverse event severity" IN 'Moderate', 'Severe' AND "Timing of adverse event" LESS THAN 30 days from "VMMC procedure date" | a) 1 b) Total number of individuals under going VMMC performed according to national standard during the reporting period | a) 1 b) COUNT of clients with a "VMMC procedure date" in the reporting period | • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years) • Type and seriousness of adverse event • Timing of adverse event (intraoperative, postoperative) • Service site • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Setting: facility-based service (including hospitals, health clinics, general practice offices, etc.) or community-based service (including drop-in centres, community service delivery points, mobile clinics or vans, outreach teams, community support groups, etc.) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.17 | PRV.17 | Condom use (key populations and general population) | • % of people who used condoms with a non-regular partner in the last 12 months (general population) • % of sex workers who used a condom the last time they had sex with a client • % of men who used a condom the last time they had anal sex with a non-regular male partner • % of trans and gender diverse people who used a condom during last anal sex with a non-regular partner • % of people who inject drugs who used a condom the last time they had sex with a partner in the last month | HIV prevention | This indicator measures the extent to which condoms are used by people who are likely to have higher risk sex. | • Condom use at last high-risk sex act gives a good indication of overall levels and trends of protected and unprotected sex. • Changes in condom use are the combined result of community norms around condom use, availability of condoms and motivation of individuals to protect themselves when engaging in sex. • Quantifying the number of unprotected high-risk sexual acts is a critical input for modelling HIV transmission. | Number of respondents reporting condom use at last specified encounter: For the general population: number of respondents who say they used a condom the last time they had sex with a non-marital, non-cohabitating (non-regular) partner in the last 12 months For sex workers: number of sex workers who report using a condom with their most recent paying client For men who have sex with men: number of men who have sex with men who report that a condom was used the last time they had anal sex with a non-regular partner in the last 6 months* For trans or gender diverse people: number of trans or gender diverse people who report that a condom was used the last time they had anal sex with a non-regular male partner in the last 6 months* For people who inject drugs: number of people who inject drugs who report that a condom was used the last time they had sex with a partner in the last 1 month* | Not included in DAK; survey-based | Number of respondents: For the general population: number of respondents who report having had sex with a non-marital, non-cohabitating partner in the last 12 months For sex workers: number of sex workers who report having commercial sex in last 12 months* For men who have sex with men: number of men who have sex with men who report having had anal sex with a non-regular male partner in the last 6 months For trans and gender diverse people: number of trans and gender diverse people who report having had anal sex with a non-regular male partner in the last 6 months For people who inject drugs: number of people who inject drugs who report having had sex with a partner in the last 1 month | • Gender (female, male, other**) • Age (<25, 25+ years) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.18 | HTS.1 | People living with HIV who know their HIV status (first 95) | Number and % of people living with HIV who know their HIV status | HIV testing services | This measures the number and percentage of people living with HIV who have been tested and know their HIV status. | • Knowledge of HIV status is the entry point for people living with HIV to treatment and the continuum of care, and for those who test HIV-negative and remain at elevated risk of HIV acquisition, to prevention interventions. • Disaggregated estimates can reveal gaps in access to testing among important groups of people living with HIV | Number of people living with HIV who have received their diagnosis and are still alive | COUNT of clients with "HIV status"='HIV-positive' AND "Date informed of HIV-positive diagnosis" before reporting period end date | Estimated number of people living with HIV | *Estimated number of people living with HIV | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • ANC attendees • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.19 | HTS.2 | HTS test volume and positivity | Number of HIV tests performed (volume) and the % of HIV-positive results returned to people (positivity) | HIV testing services | This indicator measures HIV test volume and positivity across service delivery approaches and populations. | • Knowledge of HIV status is the entry point for people living with HIV to treatment and the continuum of care, and for those who test HIV-negative and remain at risk to prevention interventions. • Testing volume disaggregated by age, sex, testing approach and HIV status helps to assess the gaps among various settings, contexts and populations and better target service delivery. | Number of tests conducted in which a new HIV-positive result or diagnosis was returned to a person during the reporting period (positivity) | COUNT of tests with "HIV test result"='HIV-positive' AND (("Date HIV test results returned" in the reporting period) OR ("HIV diagnosis date" in the reporting period)) | Number of tests performed where results were returned to a person during the reporting period (testing volume) | COUNT of tests with "HIV test date" AND "Date HIV test results returned" in the reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • TB status (presumptive TB, diagnosed TB, none) • Testing entry point: - Facility-level testing: Provider-initiated testing and counselling in clinics or emergency facilities, ANC clinics (including labour and delivery), voluntary counselling and testing (within a health facility setting), family planning clinics (only in high HIV burden settings), TB clinics, other facility-level testing - Community-level testing: Mobile testing (for example, through vans or temporary testing facilities), voluntary counselling and testing centres (not within a health facility setting), other community-based testing. • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.20 | HTS.3 | Individuals testing positive for HIV | % testing positive among people who received an HIV test in the reporting period | HIV testing services | Measures the proportion of people testing positive for HIV. Individuals receiving more than one HIV test in the reporting period are counted only once in the denominator. | Knowing the HIV test positivity among individuals by testing approach is critical to understanding the reach of HIV testing services, and the number of people aware of their status and receiving person-centred services. | Number of people who test HIV-positive in the reporting period and have results returned to them* | COUNT of clients with "HIV test result"='HIV-positive' AND "HIV test date" in the reporting period AND (("Date HIV test results returned" in the reporting period) OR ("HIV diagnosis date" in the reporting period)) | Number of people receiving an HIV test in the reporting period | COUNT of clients with "HIV test date" in the reporting period AND "Date HIV test results returned" in the reporting period | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • TB status (presumptive TB, diagnosed TB, none) • Testing entry point: - Facility-level testing: Provider-initiated testing and counselling in clinics or emergency facilities, ANC clinics (including labour and delivery), voluntary counselling and testing (within a health facility setting), family planning clinics (only in high HIV burden settings), TB clinics, other facility-level testing - Community-level testing: Mobile testing (for example, through vans or temporary testing facilities), voluntary counselling and testing (VCT) centres (not within a health facility setting), other community-based testing. • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.21 | HTS.4 | Linkage to ART | % of people newly diagnosed with HIV initiated on ART | HIV testing services | This measures the extent of linkage to care and initiation of treatment following an HIV-positive diagnoses. | • In the era of "Treat All", all people diagnosed as living with HIV should be rapidly initiated on treatment to optimize treatment outcomes and prevent new infections. • Disaggregated reporting by time since diagnosis (for example, 28 days) provides an indication of the quality of care with respect to national guidelines on when treatment should be started. | Number of people newly diagnosed with HIV and started on ART during the reporting period | COUNT of clients with "Date informed of HIV-positive diagnosis" in the reporting period AND "ART start date" in the reporting period | Number of people newly diagnosed with HIV during the reporting period | COUNT of clients with "Date informed of HIV-positive diagnosis" in the reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • TB status (presumptive TB, diagnosed TB, none) • Time to start ART (within 7, 30 or 90 days of diagnosis, as per country guidelines) • Disaggregation by time since diagnosis (for example, 28 or 90 days) provides an indication of the quality of care with respect to national guidelines on when treatment should be started • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.22 | HTS.5 | HTS partner services | Number of people who were identified and tested using partner testing services and who received their results | HIV testing services | This measures the coverage and impact of the testing cascade of services for partners and other contacts* of people living with HIV, including key population members. | • Contact testing, including among sexual partners, has been shown to increase the diagnosis of already-infected contacts and partners of newly identified HIV cases. • Among serodiscordant couples, partner notification and testing can be a critical step in preventing infection of the uninfected partner. • Contact and/or partner notification and testing should be voluntary and provided with supportive services. | For the general population: Number of elicited partners and other contacts* of people diagnosed with HIV who received HTS Additional cascade data collected: • Number of people diagnosed with HIV (index cases) offered partner services • Number of people diagnosed with HIV (index cases) accepting partner services • Number of contacts/partners of people living with HIV whose information is elicited from people diagnosed with HIV (index cases) For key populations: Number of elicited contacts1 of members of key populations who received HTS. Additional cascade data collected: • Number of key population members offered social network-based/partner services • Number of key population members accepting social network-based/partner services • Number of contacts of key population members elicited | COUNT of clients "Referred through partner services" that are a 'Partner or contact of an index case' AND "Type of contact or partner for partner services" IN 'Sexual partner', 'Drug-injecting partner' with "HIV test date" AND "Date HIV test results returned" in the reporting period | 1 | 1 | • By index case gender (male, female, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • HIV status of partner or contact (already known positive, newly diagnosed positive, negative) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.23 | HTS.6 | HIVST distribution | Total number of HIV self-test (HIVST) kits distributed during the reporting period | HIV testing services | This indicator measures trends in the distribution of HIVST kits within a country at the lowest distribution point. | • Self-testing is an increasingly common mode of HIV testing that is not captured in other indicators of HTS coverage. • Monitoring the implementation of this type of testing among target populations will help programme managers track progress and forecast the need for supportive services such as linking clients to confirmatory testing and/or ART, as needed, as well as commodity supply chain needs. | Number of individual HIVST kits distributed | COUNT of the "Number of HIV self-test kits distributed" in the reporting period | 1 | 1 | • Gender (female, male, other*) • Age (10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years).** Note: Age of consent to self-test varies by country context, which may require adaptation. • In all settings: key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people) and other priority populations*** • HIVST approach, as specified by national programme, for example, community-based, facility-based, secondary distribution (such as, by index case, key population member, ANC client) • HIVST distribution by type of sites, as specified by national programme (for example, community outreach, door-to-door, mobile, workplace, antenatal clinic, primary care, outpatient department, STI clinic, family planning clinic) • HIVST distributed for use by: self, sex partner, drug-injecting partner, social contact, other • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.24 | HTS.7 | HTS linkage to prevention | Among those testing HIV-negative and identified as being at elevated risk for HIV acquisition, % of people who receive an HIV prevention intervention within defined period | HIV testing services | Measures the proportion of people receiving HIV prevention within set period (for example, same day, 7, 14 or 28 days) after receiving a negative HIV test result. | Access to HIV prevention interventions is important to reduce the risk of HIV acquisition among individuals testing HIV-negative. Ensuring individuals at ongoing risk are successfully linked to relevant HIV prevention is an important outcome following HIV testing. | Number of people who receive an HIV prevention intervention within a defined period after receiving a negative HIV test result | COUNT of clients with "At elevated risk for HIV acquisition"=True and with "Date accessed HIV prevention intervention" within X days of "HIV test date" in the reporting period with "HIV test result"='HIV-negative' where X is 7, 14, or 28 days | Number of people testing negative for HIV in the reporting period and identified as being at elevated risk for HIV acquisition (includes people requesting/receiving any HIV prevention intervention, people from key populations, people with known risk factors or those assessed as being at risk of HIV acquisition) | COUNT of clients with "At elevated risk for HIV acquisition"=True AND with an "HIV test date" in the reporting period with "HIV test result"='HIV-negative' | • Gender (female, male, other*) • Age (<15, 15–19, 20–24, 25–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • HIV prevention intervention (including PrEP, OAMT, NSP, STI services, VMMC) • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.25 | HTS.8 | HIV retesting coverage | % of people testing HIV-negative who tested again within a defined period of time after their previous test | HIV testing services | This indicator measures the rate of retesting for HIV among those at ongoing risk of HIV acquisition. | For those individuals who test negative for HIV but are at ongoing risk of HIV acquisition, retesting is encouraged. The recommended frequency of re-testing will differ for different groups in different settings. The level of retesting examined by this indicator should aligned with national recommendations. | Number of individuals who tested HIV-negative assessed to be at elevated risk for HIV acquisition who had another HIV test within a defined period after previous test. | COUNT of clients with "At elevated risk for HIV acquisition"=True AND with a second "HIV test date" within fixed period after "HIV test date" in the reporting period with "HIV test result"='HIV-negative' | Number of people assessed as being at elevated risk for HIV acquisition (includes people requesting/receiving any HIV prevention intervention, people from key populations, people with known risk factors or those assessed as being at risk of HIV acquisition) who received an HIV-negative test result in the reporting period. | COUNT of clients with "At elevated risk for HIV acquisition"=True AND with an "HIV test date" in the reporting period with "HIV test result"='HIV-negative' | • Gender (female, male, other*) • Age (<15, 15–19, 20–24, 25–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.26 | HTS.9 | People from key populations who know their status | % of key population respondents who tested positive for HIV in the past 12 months or who know their current status | HIV testing services | This indicator measures progress in providing HIV testing services to members of key populations. | • To receive the care and treatment required to live healthy, productive lives and to reduce the chance of transmitting HIV, people living with HIV must know their HIV status. • In many countries, focussing testing and counselling on locations and populations with the highest HIV burden is the most efficient way to reach people living with HIV and ensure that they know their HIV status. | Number of respondents who know that they are living with HIV (Q3 = a) or number of respondents who report having tested for HIV in last 12 months (Q1 = b & Q2= a or b) AND the result was negative (Q3 = b) Q1. Do you know your HIV status from an HIV test? a. No, I have never been tested; b. Yes, I have been tested Q2. If yes, when were you last tested? a. In the past 6 months; b. 6–12 months ago; c. More than 12 months ago Q3. Was the result of your last test: a. Positive; b. Negative; c. Inconclusive | Not included in DAK; survey-based | Number of key population survey respondents | Not included in DAK; survey-based | • Gender (female, male, other*) • Age (10–14, 15–19, 20–24, 25–29, 30–34, 35–39,40–44, 45–49, 50+ years)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.27 | ART.1 | People living with HIV on ART | Number and % of people on ART among all people living with HIV at the end of the reporting period | HIV treatment | Measures progress towards providing ART to all people living with HIV, that is, treatment coverage, taking into account total attrition during the reporting period. | • WHO currently recommends treatment for all people living with HIV to achieve viral suppression. • This indicator is central to accountability for national health sector strategic plans, effective programme management and donor programming. • This indicator is essential to measurement of the second 95 target: that 95% of the people who know their HIV-positive status are accessing ART by 2025. | Number of people on ART at the end of the reporting period (HIV patient monitoring data from, for example, ART registers, patient records or EMRs). For key populations survey data may be required. | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True at reporting period end date | 1. To determine treatment coverage: estimated number of people living with HIV (from models, such as Spectrum AIM) 2. To gauge progress toward the second 95 target: number of people living with HIV who know their HIV status (from surveys or models) | For treatment coverage: *Estimated number of people living with HIV For progress towards 2nd 95 target: \*Estimated number of people living with HIV who know their status | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.28 | ART.2 | Total attrition from ART | Number and % of people living with HIV on ART at the end of the last reporting period and those newly initiating ART during the current reporting period who were not on ART at the end of the current reporting period | HIV treatment | Measures progress towards promoting retention on ART and mitigating loss, that is, attrition from ART. This indicator is central to understanding total attrition (loss) from ART during a reporting period and to understanding net progress towards reaching the second 95 target. | • WHO currently recommends treatment for all people living with HIV to achieve viral suppression. ART attrition analyses by treatment outcome category are essential to achieving this goal. • This indicator is central to understanding total attrition (loss) from ART during a reporting period and to understanding net progress towards reaching the second 95 target. • This indicator is closely related to ART.1 People living with HIV on ART and is measured by using the same methods and programmatic outcome classification categories. | *Number of people living with HIV reported on ART at the end of the last reporting period plus Number of people living with HIV newly initiated on ART during the current reporting period minus Total number of people living with HIV on ART at the end of the current reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True at the end of previous reporting period PLUS COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" within reporting period MINUS COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True on the reporting period end date | Number of people reported on ART at the end of the last reporting period plus those newly initiated on ART during the current reporting period | COUNT of clients with "HIV status"='HIV-positive' and "On ART"=True on previous reporting period end date PLUS COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" within the reporting period | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • Treatment outcome category (died, stopped treatment, lost to follow-up) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.29 | ART.3 | People living with HIV on ART who have suppressed viral load | % of people living with HIV on ART (for at least six months) who have virological suppression | HIV treatment | Measures clinical outcomes, specifically viral suppression of patients on ART regardless of ART initiation date. | • Viral load suppression (VLS) represents the expected outcome of ART programme services that is, the third 95 target. • VLS is also the best available measure of adherence to ART | Number of people living with HIV on ART for at least six months and with at least one routine VL test result who have virological suppression (<1000 copies/mL*) during the reporting period. | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True and "ART start date" GREATER THAN 6 months before reporting period end date AND "Date of viral load sample collection" within reporting period AND "Reason for HIV viral load test"='Routine viral load test' AND "Viral load test result" LESS THAN 1000 copies/mL | Number of people living with HIV on ART at least six months with at least one routine VL result in a medical or laboratory record during the reporting period, to monitor progress towards the third 95 target In addition, this can also be presented as the number with suppressed VL among all people living with HIV to calculate population-level viral suppression. | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True and "ART start date" GREATER THAN 6 months before reporting period end date AND "Date of viral load sample collection" within reporting period AND "Reason for HIV viral load test"='Routine viral load test' | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.30 | ART.4 | New ART patients | Number of people living with HIV who initiated ART | HIV treatment | This indicator measures the expansion of ART programmes. | • Monitoring trends in new ART patients provides managers with important information for forecasting the need for ARV and allocation of staff to ensure quality of care for ART. • Initiation of ART is one of the sentinel events for HIV surveillance. | Number of people living with HIV who initiated ART in accordance with national treatment guidelines during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "ART start date" is within reporting period | 1 | 1 | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Other priority populations • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.31 | ART.5 | Late ART initiation | % of people living with HIV who initiate ART with a CD4 count of <200 cells/mm3 | HIV treatment | Measures the proportion of people living with HIV who have AIDS at the time that they initiate ART. Often CD4 count monitoring is performed at HIV diagnosis. WHO recommends CD4 count measurement at diagnosis and same day/rapid initiation of ART for all people diagnosed with HIV. | Late initiation of ART is a risk factor for treatment failure and, therefore, is important to monitor. | Number of people living with HIV initiating ART during the reporting period with a baseline CD4 count of <200 cells/mm3 | COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" within the reporting period AND "Date of baseline CD4 count test" within the reporting period AND "Baseline CD4 count" LESS THAN 200 cells/mm^3 | Number of people living with HIV initiating ART during the reporting period who have a baseline CD4 cell count | COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" within the reporting period AND "Date of baseline CD4 count test" within the reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Other priority populations • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.32 | ART.6 | Viral load testing coverage | % of people living with HIV on ART (for at least six months) with viral load test results | HIV treatment | Assesses the extent to which VL testing is available in the country and enables appropriate interpretation of VL suppression data. This indicator is essential for monitoring access to viral load testing as well as the interpretation of the indicator ART.3 PLHIV on ART who have suppressed viral load and its representativeness. | • WHO recommends routine VL testing at six months and 12 months after ART initiation and every 12 months thereafter. • Many countries are still in the process of scaling up VL testing capacity. • This indicator is critical to decide whether VL suppression as measured through routine data is likely to be representative of all patients on ART. | Number of people living with HIV on ART with at least one routine VL test result during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "ART start date" GREATER THAN 6 months before reporting period end date AND "Date viral load test results received by client" within reporting period AND "Reason for HIV viral load test"='Routine viral load test' | Number of people living with HIV on ART for at least six months | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "ART start date" GREATER THAN 6 months before reporting period end date | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Other priority populations • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.33 | ART.7 | Early viral load testing (at six months) | Number and % of people living with HIV on ART who had a viral load result reviewed by six months after initiation of ART | HIV treatment | Measures the extent to which people newly initiating ART receive appropriate and rapid follow-up VL testing to check virologic suppression and to provide an early warning to prompt adherence support and avoid HIV drug resistance.* | • WHO currently recommends VL testing for all people living with HIV at six months after ART initiation to assess VLS and, in the event of non-suppression, to identify persons in need of intensive adherence counselling and follow-up. • Virologic suppression is essential to the 95–95–95-related impact goals. • This indicator complements the VL testing coverage (ART.6) and VL suppression (ART.3) indicators. | Number of people living with HIV on ART who were eligible for VL monitoring at six months after initiation of ART during the reporting period and who had a VL test performed and result reviewed by six months after ART initiation | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "ART start date" is within reporting period AND "Date viral load test results received by client" within 6 months of "ART start date" | Number of people living with HIV on ART eligible for VL monitoring at six months after initiation of ART during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "ART start date" is within reporting period | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • Other priority populations • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.34 | ART.8 | Appropriate second viral load test after adherence counselling | % of people living with HIV receiving ART with VL ≥1000 copies/mL who received a follow-up viral load test within three months | HIV treatment | Measures the extent to which people living with HIV with non-suppressed VL receive appropriate follow-up VL testing to check virologic suppression. | • Virologic suppression is essential to the 95–95–95-related impact goals. • This indicator complements the VL testing coverage (ART.6) and VL suppression (ART.3) indicators. | Number of people living with HIV on ART who received a follow-up VL test three months after a VL test result of ≥1000 copies/mL during the reporting period* | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "Date of viral load sample collection" within reporting period AND "Viral load test result" GREATER THAN 1000 copies/mL AND follow-up "Date of viral load sample collection" LESS THAN 3 months AFTER elevated viral load result | Number of people living with HIV on ART with VL ≥1000 copies/mL during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "Date of viral load sample collection" within reporting period AND "Viral load test result" GREATER THAN 1000 copies/mL | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)**** • ART regimen • Receipt of enhanced adherence counselling (yes/no/unknown) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.35 | ART.9 | ARV toxicity prevalence | % of ART patients with treatment-limiting ARV toxicity | HIV treatment | Measures the incidence of serious ARV toxicities among ART patients. | • As use of ARVs is scaled up, people living with HIV have the potential for prolonged exposure to ARVs and the potential to experience ARV-related toxicity. • ARV-related toxicities are some of the most common reasons reported for ART non- adherence, treatment discontinuation or substitution of drugs and, thus, are important to monitor. | Number of ART patients who have stopped treatment or switched regimen due to toxicity in the reporting period | COUNT of clients with "HIV status"='HIV-positive' with a "Date ART stopped" in the reporting period AND "Reason ART stopped"='Toxicity/side effects' PLUS COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND either "Date of switch to second-line regimen" OR "Date of switch to third-line regimen" in the reporting period with a "Reason for regimen switch"='Toxicity/side effects' PLUS COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND either "Date(s) of substitution within second-line regimen" OR "Date(s) of substitution within third-line regimen" in the reporting period AND "Reason for ARV drug regimen substitution"='Toxicity/side effects' | Number of ART patients in the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True within the reporting period | • Gender (female, male, other*) • Age (<0–4, 5–9, 10–14, 15-19,>19 years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • ART regimen • Pregnancy status • Type of toxicity (gastrointestinal, skin, peripheral neuropathy, central nervous system, weight gain, hepatic dysfunction, haematological, fatigue, headache, bone dysfunction, metabolic, kidney dysfunction) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.36 | ART.10 | People from key populations living with HIV on ART | % of key population survey respondents testing positive for HIV who are on ART | HIV treatment | This indicator measures progress towards providing ART services for members of key populations. | • This indicator is central to measuring and improving access to treatment and care services and outcomes among key populations. • It enables measurement of the second 95 target for treatment: that 95% of the people who know their HIV-positive status are accessing ART by 2030. | Number of key population respondents on ART | Not included in DAK; survey-based | Number of key population survey respondents testing positive for ART | Not included in DAK; survey-based | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Provider type (key population-led or community-led organization, public sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.37 | VER.1 | Viral suppression at labour and delivery | % of HIV-positive pregnant women who are virally suppressed at labour and delivery | Vertical transmission | This indicator measures viral suppression at the time of delivery among HIV-positive pregnant women. | • Viral suppression at the time of delivery is a service quality measure at a critical point in the vertical transmission risk period. • Two different denominators give indicators similar to general measures of viral suppression among people living with HIV: The programme-based/service delivery denominator, that is, those on ART, delivering in a facility and having a viral load test, measures the third "95" target. The population-based denominator, that is, viral load among all estimated pregnant women living with HIV, regardless of ART status or ANC/facility attendance, measures population viral load suppression (of pregnant women living with HIV). | Number of HIV-positive pregnant women on ART during pregnancy and delivering at a facility during the reporting period who were virally suppressed (<1000 copies/mL) at delivery | COUNT of clients with "HIV status"='HIV-positive' AND "Place of delivery" is a 'Health facility' AND "Delivery date" is in the reporting period AND "Date of viral load sample collection" is on "Delivery date" AND "Viral load test result" LESS THAN 1000 copies/mL | Number of HIV-positive pregnant women on ART during pregnancy who deliver at a facility during the reporting period and had a viral load test during delivery, or the estimated total number of pregnant women living with HIV | COUNT of clients with "HIV status"='HIV-positive' AND "Place of delivery" is a 'Health facility' AND "Delivery date" is in the reporting period AND "Date of viral load sample collection" is on "Delivery date" Alternatively: \*Estimated total number of pregnant women living with HIV | • Age (<15, 15–19, 20–25, 25+ years) • Timing of ART initiation (during pregnancy, on ART at first ANC visit) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.38 | VER.2 | Early infant diagnosis (EID) coverage | % of HIV-exposed infants who receive a virological test for HIV within two months (and 12 months) of birth | Vertical transmission | This indicator measures early HIV diagnosis in infants. | • High coverage of early virological testing of infants helps initiate ART early in children with confirmed HIV infection and supports counselling on efforts to prevent seroconversion of those with a negative early test result. • Current PMTCT guidelines recommend virological testing for HIV-exposed infants within two months of birth. | Number of HIV-exposed infants born during the reporting period who received a virological HIV test within two months (and 12 months) of birth | COUNT of infants who are an "HIV-exposed infant or child" with "Infant date of birth" within the reporting period AND with "Date of viral load sample collection" LESS THAN 2 months AFTER "Infant date of birth" AND "HIV test type"='Nucleic acid test for HIV' | Estimated number of HIV-positive women who delivered during the reporting period. Note: The denominator is a proxy measure for the number of infants born to HIV-infected women. | *Estimated number of HIV-positive women who delivered during the reporting period | • Test result (HIV-positive, HIV-negative, indeterminate, other) to enable calculation of the percentage positive and the percentage with an indeterminate result among HIV-exposed infants receiving a virological test • Age of infant (<2 months, 2-12 months) to allow the separate calculation of the proportion of exposed infants receiving virological testing within two months of birth and within 12 months of birth • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.39 | VER.3 | Infant ARV prophylaxis coverage | % of HIV-exposed infants who initiated ARV prophylaxis | Vertical transmission | This indicator measures the delivery of prevention services to HIV-exposed infants immediately after birth. | • ARV prophylaxis for HIV-exposed infants is critical for reducing the risk of mother-to-child transmission in the immediate postpartum period – part of Prong 3 of the PMTCT strategy. • In particular, coverage of HIV-exposed infants who are born in facilities should be very high. • When using the programme-based/service delivery denominator, the indicator measures coverage among only HIV-exposed infants who are born in facilities, which is a direct measure of a programme's ability to meet standards of care. | Number of HIV-exposed infants born within the past 12 months who were started on ARV prophylaxis at birth | COUNT of infants who are an "HIV-exposed infant or child" AND "Infant date of birth" within reporting period AND "Infant ART start date" is on"Infant date of birth" | a) Programme-based/service delivery denominator: Number of HIV-positive women who delivered in a facility within the past 12 months. B) Population-based denominator: Number of HIV-positive women who delivered within the past 12 months. | Programme-based/service delivery denominator: COUNT of women with "HIV status"='HIV-positive' AND "Place of delivery" is a 'Health facility' AND "Delivery date" within reporting period Population-based denominator: \*Estimated number of HIV-positive women who delivered during the past 12 months | • ARV drug regimen • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.40 | VER.4 | ART coverage in pregnant women | % of HIV-positive pregnant women who received ART during pregnancy and/or at labour and delivery | Vertical transmission | This indicator measures whether a recommended course of ART has been provided to HIV-positive pregnant women. | • Providing ART for HIV-positive pregnant women is a critical strategy for preventing vertical transmission of HIV. • In an era of "Treat All", all HIV-positive pregnant women should be given a recommended regimen of ART as soon as possible after diagnosis, including during labour and delivery. | Number of HIV-positive pregnant women who delivered during the reporting period and received ART during pregnancy and/or at labour and delivery | COUNT of women with "HIV status"='HIV-positive' AND "Delivery date" in the reporting period AND (("On ART"=True at labour and delivery) OR ("On ART"=True during pregnancy, for this pregnancy)) | a) Programme-based/service delivery denominator Number of HIV-positive pregnant women who delivered during the reporting period and attended ANC or had a facility-based delivery b) Population-based denominator Number of HIV-positive pregnant women who delivered during the reporting period | Programme-based/service delivery denominator: COUNT of women with "HIV status"='HIV-positive' AND "Delivery date" in the reporting period AND (had an "ANC contact date" during reporting period OR "Place of delivery" was a 'Health facility') Population-based denominator: \*Number of HIV-positive pregnant women who delivered during the reporting period | Numerator: • Timing of ART initiation (1. already on ART at first ANC visit, 2. newly on ART during pregnancy, 3. newly on ART during labour and delivery, 4. on non-recommended ART regimen) The primary indicator calculation should include ART status categories 1, 2 and 3. Removing the women in category 1 "already on ART at first ANC visit" from the numerator and denominator gives a measure of ART coverage among HIV-positive pregnant women newly diagnosed during ANC. Dividing category 2 by the sum of categories 2 and 3 gives the proportion of new ART initiations occurring during pregnancy rather than at delivery. Calculating the indicator with those in category 4 (non-recommended ARV regimen) included in the numerator gives a broader measure, that is, coverage of HIV-positive pregnant women receiving any ARV drug. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.41 | VER.5 | ART coverage in breastfeeding mothers | % of HIV-exposed breastfeeding infants whose mothers are receiving ART at 12 (and 24 months) postpartum | Vertical transmission | This indicator measures the programme's ability to reduce the risk of transmission via breastfeeding (Prong 3 of the PMTCT strategy). | • In many countries the average breastfeeding period is 18–24 months. The long breastfeeding period represents an important risk period for HIV-exposed infants. • Ensuring that HIV-positive mothers are retained on ART, especially during the breastfeeding period, is critical to sustaining the health of the mother and preventing infection of her infant. | Number of HIV-exposed breastfeeding infants whose mothers are receiving ART at 12 months (and 24 months*) postpartum | COUNT of infants who are an "HIV-exposed infant or child" AND whose mothers are "Breastfeeding" 12 months after "Delivery date" AND mothers with "On ART"=True 12 months after "Delivery date" Also reported for 24 months after "Delivery date" | Number of HIV-exposed infants attending MNCH services for a 12-month visit (and 24-month visit or first visit after the end of breastfeeding) | COUNT of infants who are an "HIV-exposed infant or child" AND [(whose mothers attend a 12-month "Maternal and child health service visit") OR (first "Maternal and child health service visit" after "Delivery date" where mother is NOT "Breastfeeding")] Also reported for mothers attending 24-month "Maternal and child health service visit" | • Age (<15, 15–19, 20–24, 25+ years) • Timing of ART initiation (already on ART at first ANC visit, newly on ART during pregnancy or labour and delivery) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.42 | VER.6 | Final outcome of PMTCT | % of HIV-exposed infants whose final HIV outcome status is known | Vertical transmission | This indicator measures quality of programme follow-up to track exposed infants and ascertain final HIV status. | • Effective PMTCT programmes must follow HIV-exposed infants until the end of the breastfeeding period to ensure that the full cascade of services and support is provided to HIV-positive mothers and their infants. • The ability to ascertain final outcome status through routine programme data across multiple points of care is a key challenge. | HIV-exposed infants born within the past 12 months (or 24 months in breastfeeding settings) who have known final HIV outcome status | COUNT of infants who are an "HIV-exposed infant or child" AND [(with an "Infant date of birth" in past 12 months) OR (with an "Infant date of birth" in past 24 months IF mothers are "Breastfeeding")] AND "Registered in birth cohort"=True AND with a "Final diagnosis of HIV-exposed infant" of NOT NULL | a) Programme-based/service delivery denominator Number of HIV-exposed infants who were born within the 12 months (or 24 months in breastfeeding settings) prior to the reporting period and registered in the birth cohort For example, for the reporting period January to December 2021 the denominator would be the number of HIV-exposed infants born between January to December 2020 in non-breast feeding settings and January to December 2019 in breastfeeding settings. b) Population-based denominator Estimated number of HIV-positive women who delivered within the past 12 months (or 24 months in breastfeeding settings) | COUNT of infants who are an "HIV-exposed infant or child" AND [(with an "Infant date of birth" within past 12 months) OR (with an "Infant date of birth" within past 24 months IF mothers are "Breastfeeding")] AND "Registered in birth cohort"=True | • Outcome status (HIV-positive, HIV-negative, no longer breastfeeding) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.43 | VER.7 | HIV prevalence among women attending ANC | % of pregnant women who are HIV-positive at the time of their first test during the current pregnancy | Vertical transmission | HIV prevalence among pregnant women attending ANC, including those who were diagnosed with HIV before their first ANC visit and those testing positive during their current pregnancy. | HIV prevalence among ANC attendees is used for surveillance to measure HIV prevalence and incidence and to monitor trends in HIV infection when the following conditions are met to ensure that HIV prevalence among ANC clients is consistently representative of HIV prevalence among all pregnant women: • ANC attendance is high and all women are recorded (for example, not missing large private-sector ANC services). • HIV testing is offered to all pregnant women and not restricted to only higher-risk women or interrupted due to stock-outs of test kits. • Only the first HIV test result is used to calculate HIV prevalence during a single pregnancy. • Women who are already known to be HIV-positive and/or are already on ART prior to their first ANC visit during a pregnancy and, therefore, are not tested for HIV, are recorded and included in routine reporting. All HIV-positive women must be included in both the numerator and denominator when calculating HIV prevalence among pregnant women. See section 5.2 4 on WHO's 2022 HIV SI Guidelines on routine antenatal HIV testing for more detail. This indicator is also useful for estimating the number of women in need of PMTCT services for programme planning purposes. | Number of ANC attendees who tested HIV-positive at their first test during the current pregnancy plus number of ANC attendees known to be HIV-positive before their first ANC visit | COUNT of "Currently pregnant" clients with "HIV test result"='HIV-positive' AND "HIV test date" on "ANC contact date" is EARLIEST within current pregnancy PLUS COUNT of clients with "HIV status"='HIV-positive' on first "ANC contact date" | Number of ANC attendees receiving their first HIV test during pregnancy plus number of ANC attendees known to be HIV-positive before first ANC visit | COUNT of "Currently pregnant" clients with "HIV test date" on a "ANC contact date" during current pregnancy PLUS COUNT of clients with "HIV status"='HIV-positive' on first "ANC contact date" | • Age (<15, 15–19, 20–24, 25–29, 30–34, 35–39, 40–49, 50+ years) • HIV status at first test during current pregnancy (known positive, tested HIV-negative, tested HIV-positive, not tested) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.44 | TBH.1 | TPT initiation | Number and % of eligible people living with HIV on ART who initiated TB preventive treatment | TB/HIV | This indicator measures the extent to which people on ART initiated treatment for latent TB infection. | • TB preventive treatment (TPT) is a critical component of preventing TB-related morbidity and mortality among people living with HIV. • In the wake of recent high-level global commitments and targets, this is a critical period to track the progress that countries have made in scaling up TPT coverage. | Number of ART patients who initiated TPT during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "TB preventive treatment (TPT) start date" in the reporting period | Number of ART patients who are eligible for TPT during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True at end of last reporting period AND "Eligible for TB preventive treatment"=True | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Type of TPT regimen • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.45 | TBH.2 | TPT completion | Number and % of people living with HIV on ART who completed a course of TB preventive treatment among those who initiated TPT | TB/HIV | This indicator measures the effectiveness of scaled-up TPT programmes by assessing the proportion of patients who completed the recommended course of TPT. | • Many countries have made progress in initiating eligible people living with HIV on TPT. However, rates of TPT completion remain poor or unknown. • Assessment of TPT completion is a critical element of the TB/HIV cascade of services. | Number of ART patients who completed a course of TPT during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "TB preventive treatment (TPT) start date" in the previous period AND "TB preventive treatment (TPT) status"='Completed' | Number of ART patients who initiated any course of TPT during the previous reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "TB preventive treatment (TPT) start date" in the prior reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Type of TPT regimen • ART initiation (<12 months on ART, 12+ months on ART) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.46 | TBH.3 | TB diagnostic testing type | % of people living with HIV with TB symptoms who receive a rapid molecular test, for example, Xpert MTB/RIF, as a first test for diagnosis of TB | TB/HIV | This indicator measures the proportion of people living with HIV who screen positive for TB symptoms who receive a recommended test for diagnosis of TB. | • People living with HIV should be screened for TB symptoms and, if found positive, be tested for TB. • WHO recommends rapid-diagnostic molecular tests, for example, Xpert MTB/RIF, as the first test for diagnosis of TB among people living with HIV. | Number of people living with HIV and having TB symptoms who were tested using a rapid molecular test (for example, Xpert MTB/RIF) as a first test during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND "TB diagnostic test category"='mWRD test for TB' | Number of people living with HIV who are screened for TB and found to have symptoms during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Pregnant or breastfeeding women • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.47 | TBH.4 | People living with HIV with active TB disease | % of people living with HIV newly initiated on ART who have active TB disease | TB/HIV | This indicator measures the burden of active TB disease among people living with HIV who are newly initiated on ART. | • Early detection of TB among people living with HIV enables prompt TB treatment and early ART. • This indicator also measures indirectly the extent of efforts to detect HIV-associated TB. | Number of people living with HIV newly initiated on ART during the reporting period who have active TB disease. "Newly initiated on ART" is defined as the number of people living with HIV who start ART in accordance with national treatment guidelines during the reporting period. | COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" in the reporting period AND "Date of TB diagnosis" in the reporting period | Number of people living with HIV new on ART during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "ART start date" in reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50+ years)** • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Pregnant women or breastfeeding women • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.48 | DFT.1 | TB screening coverage among new ART patients | % of people living with HIV newly initiated on ART who were screened for TB | TB/HIV | This indicator measures the extent to which people living with HIV newly initiated on ART are screened for active TB disease. | • Routine TB screening among people living with HIV newly initiated on ART and those who are already on ART is essential to identifying presumptive TB cases in need of confirmatory diagnostic testing and to determine eligibility for TPT if active TB disease is ruled out. • Screening is most critical at the time of ART initiation, when immune compromise is greatest. It is most commonly done as a part of pre-treatment clinical assessment. • It is important to understand the cascade from ART enrolment to treatment of active TB disease; this indicator will highlight any obstacles between ART enrolment and screening for TB symptoms. • This is the first of five "screening cascade" indicators considered priority for high burden TB/HIV settings. | Number of people living with HIV newly initiated on ART who were screened for TB during the reporting period "Newly initiated" is defined as the number of people living with HIV who start ART in accordance with national treatment guidelines during the reporting period. | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period | Number of people living with HIV who newly initiated ART during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.49 | DFT.2 | TB symptom-screened positive among new ART patients | % of people living with HIV newly initiated on ART who were screened for TB symptoms and who screened positive | TB/HIV | This indicator measures the percentage of people living with HIV newly initiated on ART and screened for symptoms of active TB disease who screen positive. | • Routine TB screening among people living with HIV newly initiated on ART and those who are already on ART is essential to identifying presumptive TB cases in need of confirmatory diagnostic testing and to determine eligibility for TPT if active TB disease is ruled out. • Screening positivity rates vary based on background TB prevalence and other epidemiological and environmental factors. However, low screening positivity rates can signal inadequate or poor-quality TB screening, particularly in high burden settings. • It is important to understand the cascade from ART enrolment to treatment of active TB disease; this indicator will highlight obstacles between ART enrolment and screening for TB symptoms. • This is the second of five "screening cascade" indicators considered priority for high burden TB/HIV settings. | Number of people living with HIV newly initiated on ART who screened positive for TB symptoms | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' | Number of people living with HIV newly initiated on ART during the reporting period who were screened for TB symptoms | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period | • Gender (female, male, other*) • Age 0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.50 | DFT.3 | TB testing among those symptom-screened positive | % of people living with HIV newly initiated on ART and screened positive for TB symptoms who then are tested for TB | TB/HIV | This indicator measures the percentage of people living with HIV newly initiated on ART and screened positive for TB symptoms who then had clinical evaluation and/or appropriate TB diagnostic testing. | • Appropriate TB diagnostic testing is essential for people living with HIV who symptom- screen positive for TB. • It is important to understand the cascade from ART enrolment to treatment of active TB disease; this indicator will shed light on any obstacles between positive screening for TB symptoms and proper diagnostic testing, based on national clinical guidelines. • This is the third of five "screening cascade" indicators considered priority for high burden TB/HIV settings. | Number of people living with HIV newly initiated on ART who are investigated for active TB disease with appropriate diagnostic testing* | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND a "TB diagnostic test category" is NOT NULL AND with a "TB diagnostic test date" in the reporting period | Number of people living with HIV newly initiated on ART and screened positive for TB symptoms during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' | • Gender (male, female, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • Cities and other administrative regions of epidemiologic importance Consider disaggregating the type of diagnostic testing, for example, GeneXpert testing, LF-LAM, sputum acid-fast bacilli (AFB) examination (alone) or other diagnostic testing. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.51 | DFT.4 | TB diagnosis among those tested for TB | % of people living with HIV newly initiated on ART and tested for TB who are diagnosed with active TB disease | TB/HIV | This indicator measures the percentage of people living with HIV newly initiated on ART and, having screened positive for active TB disease, were evaluated and/or had appropriate TB diagnostic testing and were confirmed to have active TB disease. | • Appropriate TB diagnostic testing based on national clinical/WHO guidelines is essential for people living with HIV who screen positive for TB. • It is important to understand the cascade from ART enrolment to treatment of active TB disease; this indicator will highlight any obstacles between diagnostic testing and TB diagnosis. • This is the fourth of five "screening cascade" indicators considered priority for high burden TB/HIV settings. | Number of people living with HIV newly initiated on ART who were diagnosed as having active TB disease | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND a "TB diagnostic test category" is NOT NULL AND with a "TB diagnostic test date" in the reporting period AND "Date of TB diagnosis" in the reporting period | Number of people living with HIV who newly initiated ART and screened positive for TB symptoms who had appropriate diagnostic testing during the reporting period* | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND a "TB diagnostic test category" is NOT NULL AND with a "TB diagnostic test date" in the reporting period | • Gender (female, male, other**) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)*** • Cities and other administrative regions of epidemiologic importance Note: This indicator is related to but distinct from indicator TB.4 Percentage of people living with HIV newly initiated on ART who have active TB disease. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.52 | DFT.5 | TB treatment initiation among diagnosed | % of people living with HIV newly initiated on ART and diagnosed with active TB who initiated TB treatment | TB/HIV | This indicator measures the percentage of people living with HIV newly initiated on ART and, having screened positive for TB symptoms and had appropriate TB diagnostic testing that confirmed a diagnosis of active TB disease, then initiated TB treatment. | • Once active TB disease is diagnosed, it is essential that TB treatment is promptly initiated and that quality clinical monitoring is provided (according to national clinical guidelines) to ensure treatment completion. • It is important to understand the cascade from screening to treatment of active TB disease; this indicator will highlight any barriers between diagnosis and treatment. • This is the fifth of five "screening cascade" indicators considered priority for high burden TB/HIV settings. | Number of people living with HIV newly initiated on ART who were diagnosed with TB and who started treatment for active TB disease | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND a "TB diagnostic test category" is NOT NULL AND with a "TB diagnostic test date" in the reporting period AND "Date of TB diagnosis" AND "TB treatment start date" in the reporting period | Number of people living with HIV newly initiated on ART who were diagnosed with active TB disease | COUNT of clients with "HIV status"='HIV-positive' AND with "ART start type"='First-time user of ART' AND with "ART start date" in the reporting period AND "TB screening date" in the reporting period AND "TB screening result"='Screen positive for TB' AND a "TB diagnostic test category" is NOT NULL AND with a "TB diagnostic test date" in the reporting period AND "Date of TB diagnosis" in the reporting period | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.53 | DSD.1 | Multi-month ARV dispensing | % of people living with HIV and On ART who are receiving multi-month dispensing of ARV medicine during the reporting period | Differentiated service delivery | Percentage of all people living with HIV and On ART who received a multi-month supply of ARV medicine (as specified below) at their most recent ARV medicine pick-up. | • The recommendation for people living with HIV who are established on ART (see "Definitions," below) to receive multiple months of ARV medicines is a key component of care that responds to the needs and preferences of people living with HIV. For people living with HIV who are established on ART, multi-month dispensing has the potential to improve health outcomes and support long-term treatment adherence, while also reducing unnecessary clinic attendance, thus contributing to system efficiency. Broadly, multi-month dispensing can contribute to efforts to achieve the 95–95–95 targets. • Adoption and rollout of multi-month dispensing as part of national government strategies and plans is increasing. Since 2016 DSD - including the option of multi-month dispensing - is recommended in WHO HIV treatment and public health guidelines. The extent to which these models of care have been scaled up in many countries is uncertain. Reporting on this indicator will support efforts to expand the offer of multi-month dispensing. | Number of people living with HIV and On ART who received 3-5 or >6 months of ARV medicine at their most recent ARV medicine pick-up. (The number receiving <3 months of ARV supply is also collected, for validation purposes.) If countries cannot report on the number of months of ARV medicine dispensed by the disaggregations described above, they could, as an alternative, report the total number of people currently on ARV therapy and receiving ≥3 months of ARV medicine at their last medicine pick-up. | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND (("Number of days medications prescribed">=3months) for last ART prescription | Number of people living with HIV and On ART | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True within the reporting period | • Gender (female, male, other*) • Age (0–4, 5–14, 15–24, 25+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.54 | DSD.2 | Uptake of DSD ART models among people living with HIV | % of people newly enrolled in DSD ART models among those eligible | Differentiated service delivery | Uptake of DSD ART models among people living with HIV and On ART who are newly eligible for DSD ART | • It can be useful to track the uptake of DSD ART models among eligible people living with HIV on ART in order to compare trends in new enrolment in DSD ART over time. • For facilities with paper-based reporting, collecting a denominator (in this case, number of people on ART newly eligible for DSD ART) would be onerous. Therefore, this measure is a count (no denominator) where paper tools are used. | Number of people on ART newly enrolled in DSD ART models during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "DSD ART start date" within the reporting period | Number of people on ART newly eligible* for DSD ART models during the reporting period. For facilities with electronic health information systems, it is possible to measure uptake as a proportion of all people living with HIV eligible for DSD. No denominator for facilities with paper-based reporting systems | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "Date DSD ART eligibility assessed" within the reporting period AND "Eligible for DSD ART"=True | • Gender (female, male, other**) • Age (0–4, 5–14, 15–24, 25+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Category of DSD model (group models managed by health care workers, group models managed by clients, individual models based at facilities, and individual models not based at facilities). This requires each DSD ART model of care to be assigned to one of these categories to enable disaggregation. • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.55 | DSD.3 | Coverage of DSD ART models among people living with HIV on ART | % of people living with HIV enrolled in DSD ART models among those eligible for DSD ART (for facilities with electronic HIS) or among people living with HIV On ART (facilities with paper-based systems) during the reporting period | Differentiated service delivery | This indicator measures the rollout and implementation of DSD models of ART during the reporting period. | • WHO recommends DSD models of care for eligible individuals to ensure that care meets the diversity of needs among people living with HIV. • This indicator measures whether individuals who are eligible for DSD ART are receiving such services. | Number of people living with HIV enrolled in DSD ART models during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "Currently enrolled in DSD ART model"=True | Facilities with electronic health information systems: Number of people living with HIV on ART eligible for DSD ART models during the reporting period Facilities with paper-based systems: Number of people living with HIV receiving ART at the end of the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "Date DSD ART eligibility assessed" within the reporting period AND "Eligible for DSD ART"=True | • Gender (female, male, other*) • Age (0–4, 5–14, 15–24, 25+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Category of DSD model (group models managed by health care workers, group models managed by clients, individual models based at facilities, and individual models not based at facilities). This requires each DSD ART model of care to be assigned to one of these categories to enable disaggregation. • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.56 | DSD.4 | Retention in DSD ART models | % of people retained in DSD ART models during the reporting period | Differentiated service delivery | Retention in DSD ART models among people living with HIV every 12 months after enrolment This indicator is limited to facilities with electronic health information systems, as reporting would be onerous for facilities with paper-based reporting systems. | As DSD ART is scaled up, it is important to monitor retention on treatment to ensure clinical outcomes at least equivalent with conventional care. | Number of people on ART known to be on treatment 12 months after enrolling in a DSD ART model* (also at 24, 36, 48, 60 months, etc. after enrolment in the model) | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "DSD ART start date">X months before reporting period end date AND "Currently enrolled in DSD ART model"=True Reported where 'X' is 12, 24, 36, 48, or 60 months | Number of people on ART enrolled in a DSD ART model 12 months ago, excluding individuals who transferred out (also 24, 36, 48, 60 months ago, etc.) | COUNT of clients with "HIV status"='HIV-positive' AND "On ART"=True AND "DSD ART start date">X months before reporting period end date Reported where 'X' is 12, 24, 36, 48, or 60 months | • Gender (female, male, other**) • Age (0–4, 5–14, 15–24, 25+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.57 | DSD.5 | Viral suppression among people living with HIV engaged in DSD ART models | % of people living with HIV engaged in DSD ART models who have virological suppression | Differentiated service delivery | Measures HIV viral suppression at six months and 12 months after ART initiation and yearly thereafter among people living with HIV enrolled in DSD ART models This indicator is limited to facilities with electronic health information systems and would be monitored in addition to viral load suppression by ART cohort for all people living with HIV and on ART. | • Enables monitoring of viral load suppression by cohort of people living with HIV enrolled in DSD models for ART and progress towards the third 95 target • Viral load suppression is also the best available measure of patient adherence to ART. | Number of people enrolled in a DSD ART model with at least one routine viral load test during the reporting period who have virological suppression (<1000 copies/mL) at 6 months after ART initiation and yearly thereafter (that is, at 24, 36, 48 and 60 months, etc. after ART initiation). | COUNT of clients with "Currently enrolled in DSD ART model"=True AND "Date of viral load sample collection" during the reporting period AND "Reason for HIV viral load test"='Routine viral load test' AND "Viral load test result" LESS THAN 1000 copies/mL | Number of people enrolled in a DSD ART model with at least one routine viral load result in a medical or laboratory record during the reporting period | COUNT of clients with "Currently enrolled in DSD ART model"=True AND "Date of viral load sample collection" during the reporting period AND "Reason for HIV viral load test"='Routine viral load test' | • Gender (female, male, other*) • Age (0–4, 5–14, 15–24, 25+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.58 | STI.1A | Syphilis testing coverage, HIV prevention services | % of people attending HIV prevention services who were tested for syphilis during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis during the reporting period B: % of people living with HIV who were tested for syphilis during the reporting period C: % of pregnant women who were tested for syphilis during the reporting period | • Measuring the burden of syphilis among people living with HIV and among populations at elevated risk of HIV acquisition can help national planners determine the resources needed to address both diseases. • Testing pregnant women for syphilis is important for their own health, and it is also the first step in the prevention of vertical transmission of syphilis. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. • Testing for syphilis identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of people attending HIV prevention services tested for syphilis during the reporting period | COUNT of clients with "Syphilis test date" in the reporting period | Number of people attending HIV prevention services during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.59 | STI.1B | Syphilis testing coverage, HIV-positive clients | % of people living with HIV who were tested for syphilis during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis during the reporting period B: % of people living with HIV who were tested for syphilis during the reporting period C: % of pregnant women who were tested for syphilis during the reporting period | • Measuring the burden of syphilis among people living with HIV and among populations at elevated risk of HIV acquisition can help national planners determine the resources needed to address both diseases. • Testing pregnant women for syphilis is important for their own health, and it is also the first step in the prevention of vertical transmission of syphilis. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. • Testing for syphilis identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of people living with HIV tested for syphilis while attending HIV care and treatment services | COUNT of clients with "HIV status"='HIV-positive' AND with "Syphilis test date" in the reporting period | Number of people living with HIV attending HIV care and treatment services | COUNT of clients with "HIV status"='HIV-positive' with a "Visit date" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.60 | STI.1C1 | Syphilis testing coverage, pregnant women, first ANC visit | % of pregnant women who were tested for syphilis on first ANC services visit during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis during the reporting period B: % of people living with HIV who were tested for syphilis during the reporting period C: % of pregnant women who were tested for syphilis during the reporting period | • Measuring the burden of syphilis among people living with HIV and among populations at elevated risk of HIV acquisition can help national planners determine the resources needed to address both diseases. • Testing pregnant women for syphilis is important for their own health, and it is also the first step in the prevention of vertical transmission of syphilis. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. • Testing for syphilis identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of pregnant women tested for syphilis while attending their first ANC services visit | COUNT of pregnant women with first "ANC contact date" for this pregnancy in reporting period AND "Syphilis test date" on first "ANC contact date" | Number of pregnant women attending first ANC services visit | COUNT of pregnant women with first "ANC contact date" in reporting period | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.61 | STI.1C2 | Syphilis testing coverage, pregnant women, any ANC visit | % of pregnant women who were tested for syphilis on any ANC visit during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis during the reporting period B: % of people living with HIV who were tested for syphilis during the reporting period C: % of pregnant women who were tested for syphilis during the reporting period | • Measuring the burden of syphilis among people living with HIV and among populations at elevated risk of HIV acquisition can help national planners determine the resources needed to address both diseases. • Testing pregnant women for syphilis is important for their own health, and it is also the first step in the prevention of vertical transmission of syphilis. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. • Testing for syphilis identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of pregnant women tested for syphilis while attending any ANC services | COUNT of pregnant women with "ANC contact date" in reporting period AND "Syphilis test date" on ANY "ANC contact date" for this pregnancy | Number of pregnant women attending ANC services | COUNT of pregnant women with "ANC contact date" in reporting period | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.62 | STI.2A | Syphilis test positivity, HIV prevention services | % of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period B: % of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period C: % of pregnant women who were tested for syphilis and had a positive test result during the reporting period | • Syphilis test positivity can be used to identify areas within a country that require additional support and can provide early warning of potential changes in HIV and STI transmission in the general population. • Syphilis test positivity data are an important source for generating national, regional and global incidence and prevalence estimates for syphilis and congenital syphilis. | Number of people attending HIV prevention services who tested positive for syphilis during the reporting period (tested positive on both nontreponemal and treponemal tests or tested positive on either nontreponemal or treponemal test) | COUNT of clients with "Syphilis test date" in the reporting period AND "Syphilis test result"='Positive' | Number of people attending HIV prevention services tested for syphilis | COUNT of clients with "Syphilis test date" on "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP service) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.63 | STI.2B | Syphilis test positivity, HIV-positive clients | % of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period B: % of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period C: % of pregnant women who were tested for syphilis and had a positive test result during the reporting period | • Syphilis test positivity can be used to identify areas within a country that require additional support and can provide early warning of potential changes in HIV and STI transmission in the general population. • Syphilis test positivity data are an important source for generating national, regional and global incidence and prevalence estimates for syphilis and congenital syphilis. | Number of people living with HIV who tested positive for syphilis during the reporting period (tested positive on both nontreponemal and treponemal tests or tested positive on either nontreponemal or treponemal test) | COUNT of clients with "HIV status"='HIV-positive' AND with "Syphilis test date" in the reporting period AND "Syphilis test result"='Positive' | Number of people living with HIV tested for syphilis while attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Syphilis test date" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.64 | STI.2C1 | Syphilis test positivity, pregnant women, first visit | % of pregnant women who tested positive for syphilis during first ANC services visit in the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period B: % of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period C: % of pregnant women who were tested for syphilis and had a positive test result during the reporting period | • Syphilis test positivity can be used to identify areas within a country that require additional support and can provide early warning of potential changes in HIV and STI transmission in the general population. • Syphilis test positivity data are an important source for generating national, regional and global incidence and prevalence estimates for syphilis and congenital syphilis. | Number of pregnant women who tested positive for syphilis on first ANC services visit during the reporting period (tested positive on both nontreponemal and treponemal tests or tested positive on either nontreponemal or treponemal test) | COUNT of pregnant women with first "ANC contact date" for this pregnancy in the reporting period AND with "Syphilis test date" on first "ANC contact date" AND "Syphilis test result"='Positive' | Number of pregnant women tested for syphilis while attending first ANC services visit during the reporting period | COUNT of pregnant women with first "ANC contact date" for this pregnancy in the reporting period AND with "Syphilis test date" on first "ANC contact date" | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.65 | STI.2C2 | Syphilis test positivity, pregnant women, any visit | % of pregnant women who tested positive for syphilis during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for syphilis and had a positive syphilis test result during the reporting period B: % of people living with HIV who were tested for syphilis and had a positive syphilis test result during the reporting period C: % of pregnant women who were tested for syphilis and had a positive test result during the reporting period | • Syphilis test positivity can be used to identify areas within a country that require additional support and can provide early warning of potential changes in HIV and STI transmission in the general population. • Syphilis test positivity data are an important source for generating national, regional and global incidence and prevalence estimates for syphilis and congenital syphilis. | Number of pregnant women who tested positive for syphilis during the reporting period (tested positive on both nontreponemal and treponemal tests or tested positive on either nontreponemal or treponemal test) | COUNT of pregnant women with "ANC contact date" in reporting period AND with "Syphilis test date" on ANY "ANC contact date" for this pregnancy AND "Syphilis test result"='Positive' | Number of pregnant women tested for syphilis while attending ANC services during the reporting period | COUNT of pregnant women with "ANC contact date" in reporting period AND with "Syphilis test date" on ANY "ANC contact date" for this pregnancy | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.66 | STI.3A | Syphilis treatment coverage, HIV prevention services | % of people attending HIV prevention services tested positive for syphilis who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for syphilis and were treated based on national guidelines during the reporting period B: % of people living with HIV who tested positive for syphilis and were treated based on national guidelines during the reporting period C: % of pregnant women who tested positive for syphilis and were treated based on national guidelines during the reporting period | Prompt treatment of individuals positive for syphilis is important for improving their health and reducing sexual and vertical transmission of syphilis. | Number of people attending HIV prevention services who tested positive for syphilis and were treated based on national guidelines during the reporting period | COUNT of clients with "Syphilis test date" in the reporting period AND "Syphilis test result"='Positive' AND "Syphilis treatment start date" in the reporting period | Number of people attending HIV prevention services who tested positive for syphilis during the reporting period | COUNT of clients with "Syphilis test date" on "Date accessed HIV prevention intervention" in the reporting period AND "Syphilis test result"='Positive' | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.67 | STI.3B | Syphilis treatment coverage, HIV-positive clients | % of people living with HIV tested positive for syphilis who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for syphilis and were treated based on national guidelines during the reporting period B: % of people living with HIV who tested positive for syphilis and were treated based on national guidelines during the reporting period C: % of pregnant women who tested positive for syphilis and were treated based on national guidelines during the reporting period | Prompt treatment of individuals positive for syphilis is important for improving their health and reducing sexual and vertical transmission of syphilis. | Number of people living with HIV who tested positive for syphilis and were treated based on national guidelines during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Syphilis test date" in the reporting period AND "Syphilis test result"=Positive' AND "Syphilis treatment start date" in the reporting period | Number of people living with HIV who tested positive for syphilis during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Syphilis test date" in the reporting period AND "Syphilis test result"='Positive' | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.68 | STI.3C1 | Syphilis treatment coverage, pregnant women, first ANC visit | % of pregnant women tested positive for syphilis on first ANC services visit who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for syphilis and were treated based on national guidelines during the reporting period B: % of people living with HIV who tested positive for syphilis and were treated based on national guidelines during the reporting period C: % of pregnant women who tested positive for syphilis and were treated based on national guidelines during the reporting period | Prompt treatment of individuals positive for syphilis is important for improving their health and reducing sexual and vertical transmission of syphilis. | Number of pregnant women who tested positive for syphilis on first ANC services visit and were treated based on national guidelines during the reporting period | COUNT of pregnant women with first "ANC contact date" for this pregnancy in the reporting period AND "Syphilis test date" on first "ANC contact date" AND "Syphilis test result"='Positive' AND "Syphilis treatment start date" in the reporting period | Number of pregnant women who tested positive for syphilis on first ANC services visit during the reporting period | COUNT of pregnant women with first "ANC contact date" for this pregnancy in the reporting period AND "Syphilis test date" on first "ANC contact date" AND "Syphilis test result"='Positive' | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.69 | STI.3C2 | Syphilis treatment coverage, pregnant women, any ANC visit | % of pregnant women who tested positive for syphilis who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for syphilis and were treated based on national guidelines during the reporting period B: % of people living with HIV who tested positive for syphilis and were treated based on national guidelines during the reporting period C: % of pregnant women who tested positive for syphilis and were treated based on national guidelines during the reporting period | Prompt treatment of individuals positive for syphilis is important for improving their health and reducing sexual and vertical transmission of syphilis. | Number of pregnant women who tested positive for syphilis and were treated based on national guidelines during the reporting period | COUNT of pregnant women with "ANC contact date" in reporting period AND "Syphilis test date" on ANY "ANC contact date" for this pregnancy AND "Syphilis test result"='Positive' AND "Syphilis treatment start date" in the reporting period | Number of pregnant women who tested positive for syphilis during the reporting period | COUNT of pregnant women with "ANC contact date" in reporting period AND "Syphilis test date" on ANY "ANC contact date" for this pregnancy AND "Syphilis test result"='Syphilis positive' | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.70 | STI.4A | Gonorrhoea testing coverage, HIV prevention services | % of people attending HIV prevention services tested for gonorrhoea during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for gonorrhoea (molecular test, culture or POC test) during the reporting period B: % of people living with HIV who were tested for gonorrhoea (using a molecular test, culture or POC test) during the reporting period | • Infection with an acute bacterial sexually transmitted infection such as gonorrhoea is a marker of unprotected sexual intercourse and facilitates HIV transmission and acquisition. • Measuring the burden of gonorrhoea among people living with HIV and among populations at risk of HIV can help national planners determine the resources needed to address both diseases. • Testing for gonorrhoea identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of people attending HIV prevention services tested for gonorrhoea (using a molecular test, culture or POC test) | COUNT of clients with "Gonorrhoea test date" in the reporting period | Number of people attending HIV prevention services during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP) • Diagnostic test used and anatomic site sampled • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.71 | STI.4B | Gonorrhoea testing coverage, HIV-positive clients | % of people living with HIV tested for gonorrhoea during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for gonorrhoea (molecular test, culture or POC test) during the reporting period B: % of people living with HIV who were tested for gonorrhoea (using a molecular test, culture or POC test) during the reporting period | • Infection with an acute bacterial sexually transmitted infection such as gonorrhoea is a marker of unprotected sexual intercourse and facilitates HIV transmission and acquisition. • Measuring the burden of gonorrhoea among people living with HIV and among populations at risk of HIV can help national planners determine the resources needed to address both diseases. • Testing for gonorrhoea identifies individuals who would benefit from treatment. • Testing coverage measures progress towards scaling up screening/testing and can be used to assess whether national screening guidelines are being followed. | Number of people living with HIV tested for gonorrhoea (using a molecular test, culture or POC test) while attending HIV care and treatment services | COUNT of clients with "HIV status"='HIV-positive' AND "Gonorrhoea test date" in the reporting period | Number of people living with HIV attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' with a "Visit date" in reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Diagnostic test used and anatomic site sampled • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.72 | STI.5A | Gonorrhoea test positivity, HIV prevention services | % of people who tested positive for gonorrhoea during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for gonorrhoea and had a positive test result during the reporting period B: % of people living with HIV who were tested for gonorrhoea and had a positive test result during the reporting period | • Gonorrhoea test positivity can be used to highlight areas within a country that require additional support and provide early warning of potential changes in HIV and sexually transmitted infection transmission in the general population. • Gonorrhoea test positivity is important information for generating national, regional and global incidence and prevalence estimates for gonorrhoea. • Data on gonorrhoea test positivity are important for understanding the challenges imposed by increasing resistance to currently recommended treatment options. | Number of people attending HIV prevention services who tested positive for gonorrhoea during the reporting period | COUNT of clients with "Gonorrhoea test date" in the reporting period AND "Gonorrhoea test result"='Positive' | Number of people attending HIV prevention services tested for gonorrhoea (using a molecular test, culture or POC test) during the reporting period | COUNT of clients with "Gonorrhoea test date" on "Date accessed HIV prevention intervention" in the reporting period | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP) • Diagnostic test used and anatomic site sampled • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.73 | STI.5B | Gonorrhoea test positivity, HIV-positive clients | % of people living with HIV who tested positive for gonorrhoea during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were tested for gonorrhoea and had a positive test result during the reporting period B: % of people living with HIV who were tested for gonorrhoea and had a positive test result during the reporting period | • Gonorrhoea test positivity can be used to highlight areas within a country that require additional support and provide early warning of potential changes in HIV and sexually transmitted infection transmission in the general population. • Gonorrhoea test positivity is important information for generating national, regional and global incidence and prevalence estimates for gonorrhoea. • Data on gonorrhoea test positivity are important for understanding the challenges imposed by increasing resistance to currently recommended treatment options. | Number of people living with HIV who tested positive for gonorrhoea during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Gonorrhoea test date" in the reporting period AND "Gonorrhoea test result"='Positive' | Number of people living with HIV tested for gonorrhoea (using a molecular test, culture or POC test) while attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Gonorrhoea test date" in the reporting period | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Diagnostic test used and anatomic site sampled • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.74 | STI.6A | Gonorrhoea treatment coverage, HIV prevention services | % of people attending HIV prevention services tested positive for gonorrhoea who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for gonorrhoea during the reporting period who were treated based on national guidelines B: % of people living with HIV who tested positive for gonorrhoea in the reporting period who were treated based on national guidelines | Prompt treatment of individuals positive for gonorrhoea is important for improving their health and reducing sexual and vertical transmission. Untreated gonorrhoea can result in pelvic inflammatory disease, ectopic pregnancy, infertility, blindness and disseminated disease. | Number of people attending HIV prevention services who tested positive for gonorrhoea and were treated based on national guidelines during the reporting period | COUNT of clients with "Gonorrhoea test date" in the reporting period AND "Gonorrhoea test result"='Positive' AND "Gonorrhoea treatment start date" in the reporting period | Number of people attending HIV prevention services who tested positive for gonorrhoea during the reporting period | COUNT of clients with "Gonorrhoea test date" on "Date accessed HIV prevention intervention" in the reporting period AND "Gonorrhoea test result"='Positive' | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.75 | STI.6B | Gonorrhoea treatment coverage, HIV-positive clients | % of people living with HIV tested positive for gonorrhoea who were treated based on national guidelines during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who tested positive for gonorrhoea during the reporting period who were treated based on national guidelines B: % of people living with HIV who tested positive for gonorrhoea in the reporting period who were treated based on national guidelines | Prompt treatment of individuals positive for gonorrhoea is important for improving their health and reducing sexual and vertical transmission. Untreated gonorrhoea can result in pelvic inflammatory disease, ectopic pregnancy, infertility, blindness and disseminated disease. | Number of people living with HIV who tested positive for gonorrhoea and were treated based on national guidelines during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Gonorrhoea test date" in the reporting period AND "Gonorrhoea test result"='Positive' AND "Gonorrhoea treatment start date" in the reporting period | Number of people living with HIV who tested positive for gonorrhoea during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "Gonorrhoea test date" in the reporting period AND "Gonorrhoea test result"='Positive' | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.76 | STI.7A | Presence of STI syndrome, HIV prevention services | % of people attending HIV prevention services diagnosed with a particular STI syndrome during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were diagnosed with one of five STI syndromes during the reporting period B: % of people living with HIV who were diagnosed with one of five STI syndromes during the reporting period | • Diagnosis and treatment of syndromic STIs improves health, reduces transmission of STIs and contributes to a reduction in the transmission of HIV. • In most resource-limited settings, the WHO syndromic treatment guidelines are still the standard of care when laboratory diagnosis is not available or where the results will take several days. • The WHO 2021 guidelines for the management of symptomatic infections covers five syndromes: urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, and anorectal discharge. • In countries that are looking to start collecting STI syndromic data, the STI syndromes to focus on initially are: urethral discharge syndrome, genital ulcer disease syndrome and vaginal discharge syndrome. | Number of people attending HIV prevention services diagnosed with one or more of the STI syndromes during the reporting period | COUNT of clients with "Any STI syndrome diagnosed"=True on a "Date accessed HIV prevention intervention" in reporting period | Number of people attending HIV prevention services during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP) • STI syndrome (urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, and anorectal discharge) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.77 | STI.7B | Presence of STI syndrome, HIV-positive clients | % of people living with HIV diagnosed with a particular STI syndrome during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were diagnosed with one of five STI syndromes during the reporting period B: % of people living with HIV who were diagnosed with one of five STI syndromes during the reporting period | • Diagnosis and treatment of syndromic STIs improves health, reduces transmission of STIs and contributes to a reduction in the transmission of HIV. • In most resource-limited settings, the WHO syndromic treatment guidelines are still the standard of care when laboratory diagnosis is not available or where the results will take several days. • The WHO 2021 guidelines for the management of symptomatic infections covers five syndromes: urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, and anorectal discharge. • In countries that are looking to start collecting STI syndromic data, the STI syndromes to focus on initially are: urethral discharge syndrome, genital ulcer disease syndrome and vaginal discharge syndrome. | Number of people living with HIV diagnosed with one or more of the STI syndromes during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "Any STI syndrome diagnosed"=True on a "Visit date" in reporting period | Number of people living with HIV attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' with a "Visit date" in reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • STI syndrome (urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, and anorectal discharge) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.78 | STI.8A | Repeat diagnosis of STI syndrome, HIV prevention services | % of people attending HIV prevention services diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were diagnosed with the same STI syndrome two or more times during the reporting period B: % of people living with HIV who were diagnosed with the same STI syndrome two or more times during the reporting period | Presenting with the same STI syndrome two or more times in a short period suggests that an individual was not treated appropriately, has an untreated partner or is practicing unsafe sex. | Number of people attending HIV prevention services diagnosed with a particular STI syndrome two or more times during the reporting period | COUNT of clients with "Any STI syndrome diagnosed"=True on multiple values of "Date accessed HIV prevention intervention" in reporting period | Number of people attending HIV prevention services diagnosed with a particular STI syndrome during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • HIV status (HIV-positive, HIV-negative, unknown status) • HIV prevention intervention (for example, PrEP) • STI syndrome (urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, or anorectal discharge) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.79 | STI.8B | Repeat diagnosis of STI syndrome, HIV-positive clients | % of people living with HIV diagnosed with a particular STI syndrome who were diagnosed with the same STI syndrome two or more times during the reporting period | Sexually transmitted infections | A: % of people attending HIV prevention services who were diagnosed with the same STI syndrome two or more times during the reporting period B: % of people living with HIV who were diagnosed with the same STI syndrome two or more times during the reporting period | Presenting with the same STI syndrome two or more times in a short period suggests that an individual was not treated appropriately, has an untreated partner or is practicing unsafe sex. | Number of people living with HIV diagnosed with a particular STI syndrome two or more times during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "Any STI syndrome diagnosed"=True on multiple values of "Visit date" in reporting period | Number of people living with HIV diagnosed with a particular STI syndrome during the reporting period | COUNT of clients with "HIV status"='HIV-positive' with a "Visit date" in reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • STI syndrome (urethral discharge syndrome, vaginal discharge syndrome, lower abdominal pain, genital ulcer disease syndrome, or anorectal discharge) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.80 | HEP.1A | HBV test coverage, HIV prevention services | % of people attending HIV prevention services who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) | • Measuring the HBV burden among people living with HIV and among populations at risk of HIV can help national planners determine the resources needed to address both diseases. • Testing pregnant women for HBV in pregnancy is important for their own health, and it is also the first step in the prevention of mother-to-child transmission of HBV. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. This indicator also monitors programmatic targets used for validation in countries with a targeted HBV vaccination birth dose policy. | Number of people attending HIV prevention services tested for HBsAg during the reporting period | COUNT of clients with "HBsAg test date" in the reporting period | Number of people attending HIV prevention services during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.81 | HEP.1B | HBV test coverage, HIV-positive clients | % of people living with HIV who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) | • Measuring the HBV burden among people living with HIV and among populations at risk of HIV can help national planners determine the resources needed to address both diseases. • Testing pregnant women for HBV in pregnancy is important for their own health, and it is also the first step in the prevention of mother-to-child transmission of HBV. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. This indicator also monitors programmatic targets used for validation in countries with a targeted HBV vaccination birth dose policy. | Number of people living with HIV tested for HBsAg during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "HBsAg test date" in the reporting period | Number of people living with HIV attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with a "Visit date" in the reporting period | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.82 | HEP.1C | HBV test coverage, pregnant women | % of pregnant women who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) | • Measuring the HBV burden among people living with HIV and among populations at risk of HIV can help national planners determine the resources needed to address both diseases. • Testing pregnant women for HBV in pregnancy is important for their own health, and it is also the first step in the prevention of mother-to-child transmission of HBV. Knowing the testing coverage contributes to quality assessment across the full scope of antenatal care services. This indicator also monitors programmatic targets used for validation in countries with a targeted HBV vaccination birth dose policy. | Number of pregnant women tested for HBsAg during the reporting period | COUNT of "Currently pregnant" women with "HBsAg test date" in the reporting period | Number of pregnant women attending ANC services during the reporting period | COUNT of "Currently pregnant" women with an "ANC contact date" in reporting period | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.83 | HEP.2A | HCV test coverage, HIV prevention services | % of people attending HIV prevention services who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HCV during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HCV during the reporting period (laboratory-based test or rapid test) | • Measuring the hepatitis burden among people living with HIV and in populations at risk can help national planners determine the resources needed to address both diseases. Testing for HCV co-infection among people living with HIV can inform clinicians on the need for further clinical and laboratory evaluation and the need to adapt treatment. • Disaggregated estimates can point to gaps in diagnosing people infected with HCV. | Number of people attending HIV prevention services tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period | COUNT of clients with "HCV test date" in the reporting period | Number of people attending HIV prevention services during the reporting period | COUNT of clients with "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.84 | HEP.2B | HCV test coverage, HIV-positive clients | % of people living with HIV who were tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period (laboratory-based test or rapid test) | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HCV during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HCV during the reporting period (laboratory-based test or rapid test) | • Measuring the hepatitis burden among people living with HIV and in populations at risk can help national planners determine the resources needed to address both diseases. Testing for HCV co-infection among people living with HIV can inform clinicians on the need for further clinical and laboratory evaluation and the need to adapt treatment. • Disaggregated estimates can point to gaps in diagnosing people infected with HCV. | Number of people living with HIV tested for HCV (HCV antibody, HCV RNA or HCV core antigen) during the reporting period | COUNT of clients with "HIV status"='HIV-positive' with "HCV test date" in the reporting period | Number of people living with HIV attending HIV care and treatment services during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with a "Visit date" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.85 | HEP.3A | HBsAg positivity, HIV prevention services | Percentage of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test during the reporting period | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) | • Testing for HBV identifies HIV and HBV co-infection so that HIV treatment regimens can be adjusted to treat chronic hepatitis B infection as well. • The HBsAg positivity rate in ANC attendees can be used to monitor the prevalence of HBV in the population and give an indication of the HBV burden. | Number of people attending HIV prevention services who tested positive for HBsAg during the reporting period | COUNT of clients with "HBsAg test date" on a "Date accessed HIV prevention intervention" in the reporting period AND "HBsAg test result"='HBsAg positive' | Number of people attending HIV prevention services who were tested for HBsAg during the reporting period | COUNT of clients with "HBsAg test date" on a "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.86 | HEP.3B | HBsAg positivity, HIV-positive clients | Percentage of people living with HIV who were tested for HBsAg and had a positive HBsAg test during the reporting period | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) | • Testing for HBV identifies HIV and HBV co-infection so that HIV treatment regimens can be adjusted to treat chronic hepatitis B infection as well. • The HBsAg positivity rate in ANC attendees can be used to monitor the prevalence of HBV in the population and give an indication of the HBV burden. | Number of people living with HIV who tested positive for HBsAg during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "HBsAg test date" in the reporting period AND "HBsAg test result"='HBsAg positive | Number of people living with HIV tested for HBsAg during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "HBsAg test date" in the reporting period | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.87 | HEP.3C | HBsAg positivity, pregnant women | Percentage of pregnant women who were tested for HBsAg and had a positive HBsAg test during the reporting period | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) C: % of pregnant women who were tested for HBsAg and had a positive HBsAg test result during the reporting period (laboratory-based test or rapid test) | • Testing for HBV identifies HIV and HBV co-infection so that HIV treatment regimens can be adjusted to treat chronic hepatitis B infection as well. • The HBsAg positivity rate in ANC attendees can be used to monitor the prevalence of HBV in the population and give an indication of the HBV burden. | Number of pregnant women who tested positive for HBsAg during the reporting period | COUNT of "Currently pregnant" women with "HBsAg test date" on an "ANC contact date" in the reporting period AND "HBsAg test result"='HBsAg positive' | Number of pregnant women tested for HBsAg during the reporting period | COUNT of "Currently pregnant" women with "HBsAg test date" on an "ANC contact date" in the reporting period | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith-based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.88 | HEP.4A | HCV positivity, HIV prevention services | % of people attending HIV prevention services with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HCV during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HCV during the reporting period (laboratory-based test or rapid test) | Many people living with HIV and receiving ART die from liver disease resulting from untreated HCV. Testing people living with HIV for HCV identifies HIV and HCV co-infection and allows for adaptation of treatment. Highly effective hepatitis C treatment is newly available; it has a high rate of virus clearance regardless of hepatitis C virus subtype. | Number of people attending HIV prevention services newly identified with a positive HCV test during the reporting period | COUNT of clients with "HCV test date" on a "Date accessed HIV prevention intervention" in the reporting period AND "HCV test result"='HCV positive' | Number of people attending HIV prevention services who were tested for HCV during the reporting period | COUNT of clients with "HCV test date" on a "Date accessed HIV prevention intervention" in the reporting period | • Gender (female, male, other**) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • HIV status (HIV-positive, HIV-negative, unknown status) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.89 | HEP.4B | HCV positivity, HIV-positive clients | % of people living with HIV with a positive HCV test result (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period | Viral hepatitis | A: % of people attending HIV prevention services who were tested for HCV during the reporting period (laboratory-based test or rapid test) B: % of people living with HIV who were tested for HCV during the reporting period (laboratory-based test or rapid test) | Many people living with HIV and receiving ART die from liver disease resulting from untreated HCV. Testing people living with HIV for HCV identifies HIV and HCV co-infection and allows for adaptation of treatment. Highly effective hepatitis C treatment is newly available; it has a high rate of virus clearance regardless of hepatitis C virus subtype. | Number of people living with HIV newly identified with a positive HCV test (HCV antibody, HCV RNA (PCR) or HCV core antigen) during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "HCV test date" in the reporting period AND "HCV test result"='HCV positive' | Number of people living with HIV who were tested for HCV during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND with "HCV test date" in the reporting period | • Gender (female, male, other**) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)*** • Provider type (key population-led or community-led organization, public-sector provider, other entities such as private for-profit and not-for-profit organizations, including faith- based, international, nongovernmental) • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.90 | HEP.5 | HBV treatment among people living with HIV | % of people living with HIV and diagnosed with HBV infection who are on TDF-based ART | Viral hepatitis | Percentage of people living with HIV and infected with HBV who are currently on treatment | • The prevalence of HBV is high among people living with HIV. • The use of tenofovir offers good potential for harmonizing treatment across different populations, as tenofovir + lamivudine (or emtricitabine) is the preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone for persons coinfected with HIV and HBV and also can be used among persons with TB and pregnant women. | Number of people newly started on HBV treatment (TDF) during the reporting period plus Number of people living with HIV who are already on TDF-based ART | COUNT of clients with "HIV status"='HIV-positive' AND "HBsAg test date" in the reporting period AND "HBsAg test result"=' HBsAg positive' AND "HBV treatment (TDF) start date" in the reporting period + COUNT of clients with "HIV status"='HIV-positive' AND "HBsAg test date" in the reporting period AND "HBsAg test result"=' HBsAg positive' AND "Currently on TDF-based ART" | Number of people living with HIV who were diagnosed with HBV | COUNT of clients with "HIV status"='HIV-positive' AND "HBsAg test date" in the reporting period AND "HBsAg test result"='HBsAg positive' | • Gender (male, female, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key population (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.91 | HEP.6 | HCV treatment among people living with HIV | % of people living with HIV and diagnosed with HCV infection who initiated HCV treatment (direct acting antivirals) during the reporting period | Viral hepatitis | Measures the number of people living with HIV and diagnosed with HCV infection who were evaluated for hepatitis disease progression, were found to be eligible for treatment and were placed on treatment. | The prevalence of HCV is high, especially among people living with HIV who inject drugs. Treating people living with HIV for HCV improves quality of life and life expectancy and reduces mortality. Trends over time reflect progress in treating patients. Disaggregation can indicate degree of equity in enrolment of specific priority populations. | Number of people living with HIV newly started on HCV treatment during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "HCV test date" in the reporting period AND "HCV test result"='HCV positive' AND "HCV treatment start date" in the reporting period | Number of people living with HIV diagnosed with HCV during the reporting period | COUNT of clients with "HIV status"='HIV-positive' AND "HCV test date" in the reporting period AND "HCV test result"='HCV positive' | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance • Medicine type (interferon or direct acting antivirals) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.92 | HEP.7 | HCV cured among people living with HIV | % of people living with HIV and co-infected with HCV who were confirmed to be cured of HCV during the reporting period | Viral hepatitis | Measures how many are cured among all those who completed treatment. | Short courses of HCV treatment with direct acting antivirals (DAAs) lead to cure in >90% of patients and reduce mortality. Information on sustained viral response (cure) for HCV will measure treatment effectiveness and provide an incentive system, for example, cure certificates. | Number of people living with HIV diagnosed with HCV infection who have completed HCV treatment and had a sustained virological response (SVR). SVR is assessed by a viral load measurement 12–24 weeks after the end of treatment. | COUNT of clients with "HIV status"='HIV-positive' with "HCV treatment completion date" in the reporting period AND with "HCV viral load test date" is BETWEEN '12, 24' weeks after "HCV treatment completion date" AND "HCV viral load test result"='Not detected' | Number of people living with HIV and co-infected with HCV who completed HCV treatment and were assessed for sustained virological response | COUNT of clients with "HIV status"='HIV-positive' with "HCV treatment completion date" in the reporting period AND with "HCV viral load test date" is BETWEEN '12, 24' weeks after "HCV treatment completion date" | • Gender (female, male, other*) • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** • Cities and other administrative regions of epidemiologic importance • Medicine type (interferon or direct acting antivirals) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.93 | CCA.1 | Cervical cancer screening | Number of women living with HIV who were screened for cervical cancer using any screening test | Cervical cancer | Progress towards scaling up population-based screening for the prevention of cervical cancer among women living with HIV. | To measure progress towards scaling up screening for the prevention of cervical cancer among women living with HIV. Since the screening interval between tests depends on the test used, the number of women screened may vary from year to year. | Number of women living with HIV who were screened for cervical cancer using any screening test (HPV DNA test, visual inspection with acetic acid, cytology, other) | COUNT of women with "HIV status"='HIV-positive' AND with a "Date of cervical cancer screening test" in the reporting period | 1 | 1 | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Lifetime screening test number (First in lifetime, second in lifetime, etc.) • Cities and other administrative areas of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.94 | CCA.2 | Pre-invasive cervical disease treatment | % of women living with HIV who screened positive for pre-invasive cervical disease and received treatment for it | Cervical cancer | Progress towards the treatment coverage target of 90% of women with a positive screening test receiving treatment as defined in the Global Strategy for cervical cancer elimination. | • To assess availability, access and coverage of pre-invasive cervical disease treatment among women living with HIV who were diagnosed with precancerous lesions upon screening and were deemed eligible for precancer treatment in line with the WHO recommendations for screening and treatment to prevent cervical cancer. • The WHO Global Strategy targets to eliminate cervical cancer are to vaccinate 90% of eligible girls against human papillomavirus (HPV), to screen 70% of eligible women at least twice in their lifetimes and to effectively treat 90% of those with a positive screening test or a cervical lesion, including palliative care when needed, all by 2030. | Number of women living with HIV who received treatment after screening positive for pre-invasive cervical disease and were deemed eligible for treatment in line with the WHO recommendations | COUNT of women with "HIV status"='HIV-positive' AND with a "Date of cervical cancer screening test" in the reporting period for "Cervical cancer screening outcome"='Positive for cervical precancer lesions' AND "Date of treatment for cervical precancer lesions" within 6 months of "Date of cervical cancer screening test" | Number of women living with HIV who screened positive for pre-invasive cervical disease. | COUNT of women with "HIV status"='HIV-positive' AND with a "Date of cervical cancer screening test" in the reporting period for "Cervical cancer screening outcome"='Positive for cervical precancer lesions' | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Provider type (public-sector provider, private-sector provider) • Cities and other administrative areas of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.95 | CCA.3 | Invasive cervical cancer treatment | % of women living with HIV diagnosed with invasive cancer who were treated | Cervical cancer | Progress towards increasing access to treatment for invasive cervical cancer for women living with HIV | The purpose of this indicator is to assess trends in availability and access to treatment services for invasive cervical cancer for women living with HIV. In the longer run, it is expected that the number of women living with HIV who received treatment for invasive cervical cancer will plateau and slowly decrease, as screening programmes expand detection and treatment of precancerous lesions, and coverage of human papillomavirus (HPV) vaccination increases in line with the WHO Global Strategy 90–70–90 elimination targets. | Number of women living with HIV who received treatment after being diagnosed with invasive cervical cancer | COUNT of women with "HIV status"='HIV-positive' AND "Cervical cancer diagnosis"='Invasive cervical cancer' for a "Date of diagnosis of cervical precancer lesions or invasive cervical cancer" within the reporting period AND "Invasive cervical cancer treatment method" is NOT NULL | Number of women living with HIV who were diagnosed with invasive cervical cancer | COUNT of women with "HIV status"='HIV-positive' AND "Cervical cancer diagnosis"='Invasive cervical cancer' for a "Date of diagnosis of cervical precancer lesions or invasive cervical cancer" within the reporting period | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Invasive cervical cancer treatment episode (1st in lifetime, 2nd, 3rd, 4th, etc.) • Treatment type (medical, surgical) • Cities and other administrative areas of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.96 | CCA.4 | Cervical cancer survival | Crude probability of surviving 1 year after a diagnosis of cervical cancer | Cervical cancer | This indicator measures the effectiveness of cervical cancer treatment for women diagnosed with cervical cancer. | • Surveillance of cervical cancer survival among women living with HIV is essential in monitoring the access and effectiveness of treatment and follow-up to support the needs of cancer survivors. Adequate and complete follow-up is a prerequisite to conducting a survival study. • It is calculated by assessing the percentage of women living with HIV who were diagnosed with invasive cervical cancer who were still alive 12 months after their cervical cancer diagnosis. It excludes those who were not followed for the 12-month period. In places with good retention and follow-up, 5-year survival can also be calculated, including only those individuals under observation with complete follow-up five years after their diagnosis of cervical cancer. | Number of women living with HIV still alive 12 months after receiving a diagnosis of invasive cervical cancer | COUNT of women with "HIV status"='HIV-positive' AND "Cervical cancer diagnosis"='Invasive cervical cancer' for a "Date of diagnosis of cervical precancer lesions or invasive cervical cancer" in previous 12 month reporting period | Number of women living with HIV who received a diagnosis of invasive cervical cancer within a 12-month cohort observation period | COUNT of women with "HIV status"='HIV-positive' AND "Cervical cancer diagnosis"='Invasive cervical cancer' for a "Date of diagnosis of cervical precancer lesions or invasive cervical cancer" in previous 12 month reporting period | • Age (15–19, 20–24, 25–29, 30–49, 50+ years) • Cervical cancer stage at diagnosis (0, I, II, III, IV) • Cities and other administrative areas of epidemiologic importance | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 |
| HIV.IND.97 | INC.1 | HIV incidence | Estimated number of people newly infected with HIV per 1000 uninfected population | HIV incidence | This indicator measures progress towards ending the HIV/AIDS epidemic and achieving the goal of "zero new infections". | The overarching goal of the global HIV/AIDS response is to reduce the number of people newly infected to fewer than 200 000 by 2030. | Number of people newly infected with HIV during the reporting period | Not included in DAK | Total number of uninfected population (or person-years exposed) | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25-29, 30-34, 35-39, 40-44, 45-49, 50+ years) • Probable route of transmission** (Heterosexual sex, sex between men, sex work, injecting drug use with unsterile equipment, nosocomial, vertical, other***) Or • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.98 | MOR.1 | AIDS mortality | Total number of people who have died from AIDS-related causes per 100 000 population | AIDS-related mortality | This indicator measures the impact of HIV prevention, care and treatment programmes. | In the era of "Treat All", effective diagnosis and treatment of people living with HIV should greatly reduce deaths due to AIDS-related causes. | Estimated number of people dying from AIDS-related causes during the calendar year | Not included in DAK | Total population, regardless of HIV status | • Gender (female, male, other*) • Age (0–4, 5–9, 10–14, 15–19, 20–24, 25–49, 50+ years) • Key populations (men who have sex with men, people living in prisons and other closed settings, people who inject drugs, sex workers, trans and gender diverse people)** | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.99 | SDC.1 | Avoidance of health care due to stigma and discrimination (key populations) | % of key population members who avoid health care because of stigma and discrimination. | Stigma and discrimination | This indicator measures the extent to which perceived stigma and discrimination in health care settings results in members of key populations avoiding health care. | • Health care settings are one of the most common places that members of key populations experience discrimination. • Tracking the proportion of key populations that avoid health care due to stigma and discrimination provides managers with information about where to focus efforts to reduce discrimination and perceived discrimination by service providers as well as identifying areas where service utilization by members of key populations can be improved. | Number of survey respondents from key populations who answer "yes" to any of the following: "Have you ever avoided seeking...A. any health care, B. HIV testing, C. HIV medical care, or D. HIV treatment, in the last 12 months due to any of the following: 1. fear of or concern about stigma, 2. fear or concern that someone may learn you were a [insert key population type], 3. fear of or concern about or experience of violence, 4. fear of or concern about or experience of harassment or arrest by police?" | Not included in DAK | Number of survey respondents from key populations | • Age (<25, 25+) • Key populations (men who have sex with men, people who inject drugs, sex workers, trans and gender diverse people)* | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.100 | SDC.2 | Avoidance of health care due to stigma and discrimination (people living with HIV) | % of people living with HIV who avoid health care because of stigma and discrimination | Stigma and discrimination | This indicator measures the extent to which perceived stigma and discrimination in health care settings cause people living with HIV to avoid seeking health care. | • Health care settings are one of the most common places that people living with HIV and those perceived to be living with HIV experience discrimination. • Tracking the proportion of people living with HIV who avoid health care due to stigma and discrimination provides managers with information about where to focus efforts to reduce discrimination and perceived discrimination by service providers as well as identifying areas where service utilization by people living with HIV can be improved. | Number of survey respondents living with HIV who answer "yes" to any of the following: "Have you ever avoided seeking... A. health-care, B. HIV testing, C. HIV medical care, or D. HIV treatment, in the last 12 months ...due to any of the following: 1. fear of or concern about stigma, 2. fear or concern that someone may learn that you are HIV-positive, 3. fear of or concern about or experience of violence?" | Not included in DAK | Number of survey respondents living with HIV | • Age (<25, 25+) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022 | |
| HIV.IND.101 | PRV.18 | Condom coverage | % of people identified as being at elevated risk of HIV acquisition who received condoms from a programme during the reporting period | Condom programming | Number of people receiving condoms and lubricant at least once during the reporting period | Not included in DAK | a) Programme/service provider level: Number of people who are identified as being at elevated risk of HIV acquisition (includes people requesting/receiving any HIV prevention intervention, people from key populations, people with known risk factors or otherwise assessed as being at risk of HIV acquisition) b) Population level: Estimated size of each key population (with members of the corresponding key population in the numerator) | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.102 | PRV.19 | PrEP product switching | % of pre-exposure prophylaxis (PrEP) recipients who switched dosing regimen or product during reporting period | Pre-exposure prophylaxis (PrEP) | Number of people with records of two or more prescriptions or dispensing records for different PrEP products or dosing regimens | Not included in DAK | Number of people prescribed or dispensed any form of PrEP at least once during reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.103 | PRV.20 | HIV in PrEP users | Incident HIV infections per 100 person-years (PY) of follow-up on PrEP | Pre-exposure prophylaxis (PrEP) | Number of people receiving PrEP testing positive for HIV in reporting period | Not included in DAK | Total PY of PrEP during reporting period Option: Person-time on PrEP contributed by individuals who do not retest for HIV or who are lost to follow-up can be excluded from the denominator. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.104 | PRV.21 | PrEP adverse events | Incident PrEP-related adverse events per 100 PY of follow-up on PrEP | Pre-exposure prophylaxis (PrEP) | Number of people receiving PrEP experiencing adverse events in reporting period | Not included in DAK | Total PY of PrEP use during reporting period Option: Person-time on PrEP contributed by individuals who are lost to follow-up can be excluded from the denominator. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.105 | PRV.22 | STIs in PrEP users | Incident STI cases per 100 PY of follow-up on PrEP | Pre-exposure prophylaxis (PrEP) | Number of PrEP recipients identified through syndromic or etiologic approaches as STI cases during reporting period while using PrEP | Not included in DAK | Total PY of PrEP use during reporting period Option: Person time on PrEP contributed by individuals who are lost to follow-up can be excluded from the denominator. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.106 | PRV.23 | PEP transition to PrEP | Number of people completing post- exposure prophylaxis (PEP) who transition to PrEP regimen | Pre-exposure prophylaxis (PrEP) | Number or PEP recipients who transition to PrEP regimen after completing PEP | Not included in DAK | Number of people completing course of PEP in reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.107 | PRV.24 | PrEP-related ARV toxicity | % of PrEP users who discontinued or interrupted PrEP due to toxicity | Pre-exposure prophylaxis (PrEP) | Number of people who have discontinued or interrupted PrEP due to serious antiretroviral (ARV)-associated toxicity during the reporting period | Not included in DAK | Number of people who are on PrEP during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.108 | PRV.25 | Safe injecting practices (among people who inject drugs) | % of people who inject drugs who report using new sterile injecting equipment the last time they injected | Needle–syringe programme (NSP) | Number of survey respondents who answer "yes" to both questions: 1. Have you injected drugs at any time in the past month? If yes, 2. The last time you injected drugs, did you use a sterile needle and syringe? | Not included in DAK | Number of survey respondents | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.109 | PRV.26 | OAMT take-away doses availability | % of OAMT recipients receiving take-away dose(s) during the reporting period | Opioid agonist maintenance treatment (OAMT) | Number of OAMT recipients receiving take-away dose(s) at least once during the reporting period | Not included in DAK | Number of people receiving OAMT at any point during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.110 | HTS.10 | HIV-self testing | % of people who have tested for HIV using a self-test kit | HIV testing | Number of survey respondents who have ever tested for HIV using a self-test kit | Not included in DAK | Number of survey respondents | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.111 | HTS.11 | HIV retest at ART start | % of new ART patients who were retested to verify diagnosis | HIV testing | Number of people living with HIV who have initiated ART during the reporting period who had a retest to verify HIV- positive diagnosis | Not included in DAK | Number of people living with HIV who initiated ART during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.112 | HTS.12 | HIV testing services (HTS) time to linkage to prevention | Median number of days from HIV- negative test to uptake of prevention intervention | HIV testing | Sum of the number of days from date test result was received to uptake of prevention intervention for all individuals testing negative for HIV and identified as being at elevated risk for HIV acquisition | Not included in DAK | Number of people testing negative for HIV in the reporting period and identified as being vulnerable to HIV acquisition (includes people requesting/ receiving any HIV prevention intervention, people from key populations, people with known risk factors or otherwise assessed as being at risk of HIV acquisition), excluding individuals currently on PrEP and undergoing testing as part of PrEP follow-up. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.113 | AGW.1 | AGYW HIV/SRH integration | % of adolescent girls and young women (AGYW) seeking contraception/family planning who received an HIV test | HIV testing | Number of adolescent girls and women seeking contraception/ family planning services who were tested for HIV | Not included in DAK | Number of adolescent girls and women seeking contraception/ family planning services | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.114 | ART.11 | Time to ART linkage | Median number of days from HIV-positive test to ART start date | Treatment and care | Sum of the number of days from date test result was received until ART started, for all individuals testing positive for HIV in the reporting period | Not included in DAK | Number of people testing positive for HIV in the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.115 | ART.12 | ARV medicine stock-out | % of ART sites that had stock-outs of any antiretroviral (ARV) drugs during the reporting period | Treatment and care | Number of ART sites that had a stock-out of ARV drugs during the reporting period | Not included in DAK | Total number of reporting ART sites | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.116 | ART.13 | ART adherence proxy (ARV drug refills) | % of ART patients who pick up all prescribed ARV drugs on time | Treatment and care | Number of patients who pick up all prescribed ARV drugs no more than seven days late* at the first pick-up after a defined baseline pick-up | Not included in DAK | Number of patients who picked up ARV drugs on or after the designated ART start date | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.117 | ART.14 | Appropriate switch to second-line ART | % of patients with confirmed virologic failure who are switched to second- line ART within 90 days | Treatment and care | Number of people living with HIV on ART with confirmatory viral load >1000 copies/mL who are switched to second- line ART within 90 days of the confirmatory viral load test result of >1000 copies/mL | Not included in DAK | Total number of people living with HIV on ART with confirmatory viral load test result >1000 copies/mL | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.118 | ART.15 | CTX coverage | % of eligible people living with HIV who received co- trimoxazole (CTX) | Treatment and care | Number of people living with HIV who started CTX | Not included in DAK | Number of people living with HIV newly enrolled in ART who are eligible for CTX. | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.119 | VER.8 | HTS retesting in late pregnancy | % of HIV-negative pregnant women who are retested for HIV in the third trimester | Vertical transmission | Number of pregnant women attending ANC who were retested for HIV during pregnancy or at labour and delivery after an initial negative HIV test result in the reporting period | Not included in DAK | Number of women attending ANC who had an initial negative HIV test result during pregnancy in the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.120 | VER.9 | HIV testing among pregnant women | % of pregnant women who know their HIV status | Vertical transmission | Number of pregnant women attending ANC or having a facility-based delivery in the past 12 months who had an HIV test during pregnancy or at labour and delivery or who already knew they were HIV- positive at the first ANC visit | Not included in DAK | Population-based: Estimated number of pregnant women who delivered within the past 12 months Programme-/service delivery- based: Number of pregnant women who attended ANC or had a facility-based delivery in the past 12 months | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.121 | VER.10 | ART retention PMTCT | % of known HIV-positive pregnant women retained on treatment at time of delivery | Vertical transmission | Number of HIV-positive pregnant women who were on ART at the time of delivery among those who delivered during the reporting period | Not included in DAK | Number of HIV-positive pregnant women who initiated ART during pregnancy or were already on ART at the first ANC visit and who delivered during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.122 | VER.11 | CTX coverage of exposed infants | % of HIV-exposed infants started CTX prophylaxis within two months of birth | Vertical transmission | Number of HIV-exposed infants born during the reporting period who started on CTX within two months of birth | Not included in DAK | Number of HIV-positive women who delivered during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.123 | VER.12 | Toxicity-related adverse pregnancy outcomes | % of births to HIV-positive women on ART that resulted in poor birth outcomes | Vertical transmission | Number of HIV-positive women who delivered during the reporting period who had poor birth outcomes. | Not included in DAK | Number of HIV-positive women who delivered during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.124 | VER.13 | Partner testing prevention of mother- to-child transmission (PMTCT) | % of pregnant women attending antenatal care (ANC) whose male partners know or learn their HIV status during pregnancy or the breastfeeding period | Vertical transmission | Number of pregnant women attending ANC and breastfeeding women during the reporting period whose male partners were tested (regardless of test result) or were already known to be HIV-positive | Not included in DAK | Number of pregnant women attending ANC or breastfeeding women attending postnatal clinic during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.125 | VER.14 | Turnaround time EID | % of early infant diagnosis (EID) test results returned within four weeks | Vertical transmission | Number of EID tests conducted within the reporting period with results returned within four weeks of specimen collection (or in keeping with national standard, if less than four weeks) | Not included in DAK | Number of EID test conducted during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.126 | VER.15 | Early infant ART initiation | % of identified HIV-positive infants who initiated ART on the day of diagnosis | Vertical transmission | Number of infants (<24 months of age) started on ART on the same day as receiving an HIV- positive diagnosis during the reporting period | Not included in DAK | Number of infants (<24 months of age) identified as HIV-positive during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.127 | STI.9 | Time to syphilis treatment | Median time between syphilis test (screening or confirmatory) and treatment | Sexually transmitted infections | Median number of days between syphilis screening date (or confirmatory test date if confirmatory test performed) and date treatment prescribed or dispensed | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.128 | STI.10 | Gonorrhoea repeat test positivity | % of people tested positive for gonorrhoea who tested positive again during the reporting period | Sexually transmitted infections | Number of people who tested positive for gonorrhoea two or more times during the reporting period | Not included in DAK | Number of people who tested positive for gonorrhoea (using a molecular test, culture or POC test) during the reporting period | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.129 | STI.11 | Time to gonorrhoea treatment | Median time between gonorrhoea test and treatment | Sexually transmitted infections | Median number of days between gonorrhoea test date and date treatment prescribed or dispensed | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.130 | CCA.5 | HPV vaccination among women living with HIV | Proportion of women living with HIV with completed human papilloma virus (HPV) vaccine series | Cervical cancer | Number of women living with HIV who have received a completed series of HPV vaccination* | Not included in DAK | Number of women living with HIV | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.131 | CCA.6 | Cervical cancer screening tests used | Distribution of cervical cancer screening tests | Cervical cancer | Number of women living with HIV who were screened for cervical cancer using 1) HPV DNA test; 2) visual inspection with acetic acid; 3) cytology; 4) other | Not included in DAK | Number of women living with HIV who were screened for cervical cancer using any screening test in the last 12 months | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.132 | CCA.7 | Age at first-in-lifetime cervical screen | Age at first in lifetime cervical screening test | Cervical cancer | Median age in years at first-in- lifetime cervical screening test | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.133 | CCA.8 | Cervical cancer screening interval | Time between first and second lifetime screening tests | Cervical cancer | Median time in years between first and second lifetime cervical screening tests | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.134 | CCA.9 | Cervical cancer triage test | Proportion of women living with HIV who received a triage test | Cervical cancer | Number of women living with HIV who screened positive for pre-invasive cervical disease or suspected invasive cancer who received a triage test (disaggregated by test used) | Not included in DAK | Number of women living with HIV who were screened for cervical cancer using any screening test | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.135 | CCA.10 | Time to treatment for pre-invasive cervical disease | Median time between pre-invasive cervical disease diagnosis and treatment | Cervical cancer | Median number of days between pre-invasive cervical disease diagnosis date and pre-invasive cervical disease treatment date | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.136 | CCA.11 | Time to treatment for invasive cervical disease | Median time between invasive cervical disease diagnosis and treatment | Cervical cancer | Median number of days between invasive cervical disease diagnosis and treatment date | Not included in DAK | 1 | 1 | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | |||
| HIV.IND.137 | CCA.12 | Loss to follow-up - pre-invasive cervical disease | Proportion of women living with HIV who are lost to follow- up after receiving treatment for pre-invasive cervical disease | Cervical cancer | Number of women living with HIV who received treatment for pre-invasive cervical disease who did not return for retesting 12 months after their treatment | Not included in DAK | Number of women living with HIV who received treatment for pre-invasive cervical disease 12 months ago | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.138 | QOC.6 | External quality assurance for testing | % of national reference laboratories in the country that benefit from external quality assurance of HIV testing procedures | Quality of care | Number of national reference laboratories in the country that benefit from external quality assurance of HIV testing procedures | Not included in DAK | Number of national reference laboratories in the country conducting HIV testing procedures | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.139 | QOC.7 | Documented referral & linkage to care | % of people living with HIV with documentation that they were referred to another service who actually linked to the referred service | Quality of care | Number of people living with HIV with documentation that they were referred to another service and who were confirmed to have linked to the referred service | Not included in DAK | Number of people living with HIV with documentation that they were referred to another service | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators | ||||
| HIV.IND.140 | QOC.8 | Patient preferences for end-of-life care | % of people living with HIV with life- limiting illness who were asked by a provider about their preferences for end- of-life care, defined as the last 12 months of life | Quality of care | Number of people living with HIV with life-limiting illness who were asked by a provider about their preferences for end-of-life care, defined as the last 12 months of life Potential data sources: Client satisfaction surveys, exit interviews with clients, focus group discussions. | Not included in DAK | Number of people living with HIV with life-limiting illness | Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. Geneva: World Health Organization; 2022; Web annex B - Additional Indicators |